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Abstract 
 
There are no treatments proven to significantly reduce heart failure hospitalisations or 
mortality in patients with heart failure with preserved ejection fraction (HFpEF). Activity of 
the sympathetic nervous system (SNS) is elevated in heart failure regardless of ejection 
fraction and may be an important target in HFpEF. Renal denervation (RDT) is a 
percutaneous technique that seeks to attenuate SNS activity. The aim of this thesis was to 
investigate the role of RDT in patients with HFpEF. A randomised (2:1) open-controlled trial 
with blinded endpoint analysis was planned. 
10 228 patients were screened for the Renal DenervaTion in heart failure with Preserved 
Ejection Fraction trial (RDT-PEF), and ultimately 25 were randomised (17 received RDT and 
8 were allocated to the open control arm). 
The primary endpoint was an improvement in a minimum of three out of the following six 
surrogate endpoints: Minnesota Living with Heart Failure questionnaire score, peak oxygen 
uptake on exercise, B-type natriuretic peptide, E/e‟ from echocardiography, left atrial volume 
from cardiac magnetic resonance imaging (CMR) and left ventricular mass from (CMR). The 
primary endpoint was not met but the study was underpowered.  
On post-hoc analysis there was an improvement in a composite score of all six endpoint in 
the RDT arm compared to the control arm at three months but this did not persist to 12 
months. 
The study satisfied its safety endpoints. However, two patients required balloon angioplasty 
during the RDT procedure for significant renal artery spasm/oedema. 
RDT had no effect on blood pressure, renal function, vascular function, renin-angiotensin 
system or SNS activity. 
In summary, this thesis has shown that HFpEF is not as prevalent as reported. RDT did not 
improve quality of life, exercise function, biomarkers and left heart remodelling in HFpEF. 
The procedure was safe though not without complications in patients with HFpEF. 
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1. Background: Heart Failure with Preserved Ejection 
Fraction 
 
1.1 Epidemiology 
Heart failure is prevalent and affects 2% of the developed world‟s population.[1] It is the 
commonest cause of hospitalisation in individuals above the age of 65 years[2] and 
contributes to one in nine deaths.[3] Patients with this diagnosis have a reduction in both 
quality of life[4] and life expectancy (50% of patients with the diagnosis are not expected to 
survive more than 5 years).[5, 6] Heart failure is a heterogeneous condition and has 
historically been dichotomised into two groups based upon ejection fraction (EF), those with 
heart failure and a reduced EF (HFrEF) and those with heart failure and a preserved or 
normal EF (HFpEF).[7] EF is simply the volume of blood ejected by the left ventricle in one 
heart beat divided by the volume of the left ventricle in its relaxed state (end-diastole). The 
value of using EF to classify heart failure is that for those patients with HFrEF there are 
numerous pharmacological and non-pharmacological therapies proven to improve survival 
and reduce heart failure hospitalisation.[7] However, for the remainder, the same therapy 
gave neutral results, making patients with HFpEF, a group with an unmet clinical need.[7, 8] 
The latter cohort is the focus of this thesis. 
 
1.2 Definition of Heart Failure 
The definition of heart failure has evolved over the years as understanding of its 
pathophysiology grows. The European Society of Cardiology (ESC) guidelines have defined 
it as „as a syndrome in which patients have typical symptoms (e.g. breathlessness, ankle 
swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, 
and displaced apex beat) resulting from an abnormality of cardiac structure or function.‟[7] 
 
The American Heart Association (AHA)/American College of Cardiology (ACC) guidelines 
give a similar broad definition: „Heart failure is a complex clinical syndrome that results from 
any structural or functional impairment of ventricular filling or ejection of blood.‟[9] 
 
Clinical features alone are not sufficient to secure a diagnosis of heart failure as they are often 
non-specific and may be attributed to other disease processes, e.g. severe lung disease 
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(breathlessness, pulmonary crackles), renal failure (ankle swelling, fatigue, elevated jugular 
venous pressure). 
 
Further to signs and symptoms of heart failure, to complete the diagnosis of HFrEF a 
documented EF ≤40% (AHA/ACC)[9] or ≤35% (ESC)[7] is required. 
 
1.3 Diagnosis of HFpEF 
Compared to making a diagnosis of HFrEF, diagnosing HFpEF is more complicated. Though 
broadly similar the international guidelines are not completely interchangeable (Table 1.1). 
They all mandate symptoms and signs of heart failure and a preserved or normal ejection 
fraction. The guidelines emphasize the exclusion of patients with non-cardiac causes of 
symptoms (e.g. obesity, lung disease, anaemia).[7, 9] In practice non-cardiac causes of 
symptoms often co-exist in patients with HFpEF and may even be a driving factor of the 
heart failure process, which adds to the difficulty in making a diagnosis.[10] 
 
There remain discrepancies between the guidelines with respect to the need for an elevated 
natriuretic peptide level, the requirement for left atrial or ventricular remodelling and 
diastolic dysfunction. None of these guideline-endorsed diagnostic criteria have been 
validated prospectively for their diagnostic utility on an unselected population.[11] This may 
explain the varying definitions used in observational and clinical studies. The consequence of 
this is that it is not possible to amalgamate all of the published data to make specific 
comments about this population and this must be recognised when reading the rest of this 
section in which I will review the epidemiology, prognosis, pathophysiology and trial data for 
this condition. 
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 ESC: Consensus for 
Heart Failure with 
Normal Ejection 
Fraction[10] 
ESC: Guidelines for 
Heart Failure[7] 
ACC/AHA: Guidelines 
for Heart Failure[9] 
Published 2007 2012 2013 
Clinical Signs and symptoms Signs and symptoms Signs and symptoms 
LV 
Function 
Normal or mildly 
reduced systolic function 
or 
EF>50% 
Normal or mildly 
reduced systolic function 
or  
EF≥50% 
Normal or preserved 
systolic function or 
EF≥50%, 
EF 41-49% classified                 
as borderline HFpEF 
LV Size Non dilated: 
LVEDVI < 97ml/m
2
 or 
 LVESVI < 49ml/m
2 
Non dilated: 
 LVEDVI < 97ml/m
2
 or 
 LVESVI < 43ml/m
2
 
No requirement of LV 
not to be dilated 
Diastolic 
Dysfunction 
PCWP>12mmHg or 
LVEDP>16mmHg or 
E/e‟>15 or 
E/e‟ >8 and <15 with: 
  BNP>200pg/ml or 
  Atrial fibrillation or 
  LAVI >40ml/m
2
 or 
  Increased LVMI or 
  Abnormal diastology 
 
Dilated left atrium  
  (LAVI >34ml/m
2
) or 
Left ventricular 
hypertrophy 
(LVMI>95g/m
2
 F, 
>115g/m
2
 M) and/or 
Abnormal diastology 
with or without AF 
Structural remodelling 
(not specified) 
 
No requirement for 
abnormal diastology 
Table 1.1:Three current international guidelines for the diagnosis of heart failure with 
preserved ejection fraction. EF- ejection fraction; LV- left ventricle; LVEDVI- left 
ventricular end-diastolic volume index; LVESVI- left ventricular end-systolic volume 
index; BNP- B-type natriuretic peptide, LAVI- left atrial volume index; LVMI- left 
ventricular mass index; AF- atrial fibrillation  
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1.4 Epidemiology of HFpEF 
Population studies and registries from around the world have suggested that 30-75% of the 
heart failure population have HFpEF. The large variation is related to the differing definitions 
of HFpEF employed, notably in the EF cut-off used, which varied between 40 and 55% 
(Table 1.2). In a cohort of patients with a diagnosis of heart failure from the „Get with the 
Guidelines‟ programme, the proportion with HFpEF rose from 36% to 50% when the EF cut-
off was reduced from ≥50% to ≥ 40%.[12] 
 
Other important sources of variation included: 1) The varying modalities to quantify EF 
(echocardiography [Simpson‟s biplane, Teicholz and visual qualitative], nuclear imaging, 
direct angiography); 2) Lack of standardisation in excluding other cardiac and non-cardiac 
causes of symptoms, e.g. only some of the studies excluded patients with significant valve 
disease; 3) The large proportions of patients excluded because of not having a recorded EF. 
 
From the studies presented in Table 1.2 and others, HFpEF has been suggested to be more 
common in elderly patients, females and those with greater co-morbidities.[13-16] The most 
prevalent co-morbidities in HFpEF are hypertension (60-80%), ischaemic heart disease (35-
70%), diabetes (20-45%) and atrial fibrillation (15-40%).[15] 
 
Longitudinal follow up studies have suggested that the prevalence of HFpEF is increasing 
and may reflect the ageing and greater co-morbid population in the developed world as well 
as an increased awareness of the diagnosis.[13, 15, 17] 
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Study Location HF 
Subjects 
HFpEF Diagnosis 
Criteria 
Exclusion % with 
HFpEF 
Population studies 
Gurwitz et al 
[18] 
US 11994 New onset HF 
EF≥50% 
 52 
Olmsted County 
[17] 
US 4596 HF admission 
EF≥50% 
No EF (n=1480) 47 
Heart Failure 
Survey in Israel 
[19] 
Israel 2845 HF Admission 
EF≥40% 
No EF (n=1257) 48 
EFFECT Study 
[20] 
Canada 2802 HF admission 
EF>50% 
No EF (n=6492) 
Severe valve disease 
31 
Minnesota Heart 
Survey[21] 
US 2203 HF admission 
EF≥45% 
No EF (n=2646) 36 
Tribouilloy et al 
[22] 
France 662 HF admission 
EF≥50% 
No EF (n=137) 56 
Rochester 
Epidemiology 
Project [23] 
US 556 HF admission or 
outpatients review 
EF≥50% 
 55 
Framingham 
[24] 
US 534 New onset HF  
EF>45% 
No EF (n=76) 41 
Copenhagen HF 
Study [25] 
Denmark 433 HF admission 
EF>50% 
No EF (n=127) 
Valvular heart 
disease 
ACS at time of HF 
admission 
61 
PREVEND[26] Netherlan
ds 
374 New onset HF  
EF≥50% 
 34 
Cardiovascular 
Health Study 
[27] 
US 269 HF admission or 
outpatient review 
EF≥55% 
Severe valve disease 
Age <65 
63 
Yip et al [28] Hong 
Kong 
175 HF admission 
EF>45% 
Moderate valve 
disease 
75 
Strong Heart 
Study [29] 
US 95 Outpatient review 
EF≥55% 
Age <45 
End-stage renal 
failure 
53 
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Study Location HF 
Subjects 
HFpEF Diagnosis 
Criteria 
Exclusion % with 
HFpEF 
Registries 
GWTG [12] US 110621 HF admission 
EF≥50% 
No EF (n=16631) 36 
ADHERE [30] US and 
Worldwid
e 
62134 HF admission 
EF≥40% 
No EF (n=9952) 49 
OPTIMIZE [31] US 41267 HF admission 
EF≥40% 
No EF (n=7345) 51 
Euro Heart 
Failure Survey 
[32] 
Europe 6806 HF admission 
EF≥40% 
No EF (n=3895) 46 
JCARE-CARD 
[33] 
Japan 1962 HF admission 
EF≥50% 
No EF (n=332) 
Valve disease  
26 
MISCHF [34] US 1291 HF admission 
EF≥50% 
No EF (n=1195) 
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Table 1.2: Studies providing data on HFpEF as a proportion of all heart failure. HF- 
heart failure; EF- ejection fraction; US- United States 
1.5 Prognosis of HFpEF 
Estimates of mortality rates of patients with HFpEF have varied widely in the literature but 
regardless of the exact figure they have a poorer prognosis than patients with similar co-
morbidities but without heart failure.[22, 35] Reported five year survival from 
epidemiological studies in patients with HFpEF is as low as 65%, which is similar to the 
survival of patients with HFrEF.[17, 20] However, conflicting conclusions were drawn from 
a meta-analysis of 31 clinical trials, from which mortality in patients with HFrEF was worse 
than those with HFpEF (Figure 1.1), which may reflect the differing characteristics of 
patients recruited into these trials.[36] 
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Figure 1.1: Mortality rate of patients with heart failure with reduced ejection fraction 
(HF-REF) compared to preserved ejection fraction (HF-PEF), adjusted for age, gender, 
aetiology of heart failure, hypertension, diabetes, atrial fibrillation. Reproduced from 
[36]. 
 
Approximately 30-50% of patients with HFpEF die of non-cardiovascular causes, which is a 
greater proportion than in the HFrEF population (Figure 1.2).[37] Potential explanations for 
this difference include: 1. Increased non-cardiac co-morbidities in patients with HFpEF 
compared to HFrEF; 2. Selection bias, whereby patients with significant and unstable 
coronary artery disease develop HFrEF and die a coronary (cardiovascular) death, whereas 
those with stable coronary artery disease do not have a coronary death and die subsequently 
from a non-cardiac cause.[37] 
 
Quality of life is reduced in HFpEF and to a similar extent to HFrEF patients when matched 
for natriuretic peptide levels.[38] Hospitalisation is also common in HFpEF and it is 
associated with a worse prognosis.[17, 20, 31] 
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Figure 1.2: Distribution of cardiovascular (CV) and non-cardiovascular deaths in 
patients with heart failure with reduced ejection fraction (HFREF) and preserved 
ejection fraction (PEF) across community based studies and clinical trials. Reproduced 
from [37]. 
 
1.6 Pathophysiology of HFpEF 
A complete model that explains the pathophysiological abnormalities in HFpEF is yet to be 
formulated. [39] Until recently, there even remained debate as to whether HFpEF and HFrEF 
were overlapping or distinct phenotypes in the same heart failure spectrum.[11, 40, 41] 
 
The strongest evidence that HFpEF has a different pathophysiology to HFrEF comes from 
bimodal distribution of heart failure admission (broadly based upon worsening symptoms of 
fluid overload requiring intravenous diuretics) stratified by EF across many registries (an 
example is shown in Figure 1.3).[31] If HFpEF and HFrEF were manifestations of the same 
disease process then one might expect to see a uni-modal distribution of EF.  
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Figure 1.3: Graph of 4910 consecutive patients admitted to the Mayo Clinic with heart 
failure according to ejection fraction and stratified by gender. Reproduced from [40]. 
 
Further supporting evidence arises from the knowledge that: 1) therapies known to be 
effective in HFrEF have not been shown to be effective in HFpEF; 2) there are different 
patterns of macroscopic and microscopic ventricular remodelling; and 3) the two phenotypes 
seem to afflict different populations.[13-15] Clinicians and researchers alike are now treating 
and studying HFpEF and HFrEF as separate entities. 
 
Scarcity of human myocardial tissue and the absence of a representative animal model limit 
our complete understanding of the disease processes at play in HFpEF. [42] Key 
pathophysiological abnormalities in HFpEF can be split into those affecting the heart as well 
as other organs (Figure 1.4). It is important to note that these features are not universally 
present in HFpEF patients and many of these features are also noted in HFrEF patients. 
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Figure 1.4: Pathophysiology of HFpEF: extracardiac mechanisms and organ 
interaction. Reproduced from [43]. 
 
1.6.1 Diastolic Dysfunction 
HFpEF used to be known as diastolic heart failure.[23] The nomenclature was changed as it 
did not adequately define the condition due to several factors. Firstly, only two-thirds of 
patients with HFpEF exhibit evidence of diastolic dysfunction at rest, which suggests that 
other important mechanisms might be involved in the condition.[44] Secondly, diastolic 
dysfunction becomes more prevalent with ageing and is not always associated with the heart 
failure syndrome.[45, 46] Finally, abnormalities in diastole are also commonly observed in 
patients with HFrEF and hence it is not unique to HFpEF.[47] 
 
Diastolic dysfunction is the inability to fill the left ventricle to an adequate volume at 
acceptably low pressures.[48] It is usually assessed on an echocardiogram or infrequently 
during an invasive haemodynamic cardiac catheterisation using a high-fidelity pressure-
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volume loop conductance catheter. The latter is considered by many to be the gold standard 
technique, though its clinical uptake remains limited.[49-51] The advantages of 
echocardiography include its universal availability, suitability for serial investigations, 
established role in clinical practice, patient acceptability and low cost, which make it a first 
line investigation in heart failure.[7, 9] Generally, the guidelines recommend two or more 
echocardiographic parameters to be abnormal to improve specificity in diagnosing diastolic 
dysfunction.[7] 
 
Two key processes determine diastolic dysfunction: impaired active LV relaxation and 
increased LV stiffness. The adverse haemodynamic consequence of these processes, raised 
filling pressures, is accentuated (or sometimes only uncovered [52, 53]) by factors that 
increase heart rate and/or vascular loading, which can be dynamically investigated using 
exercise[53], pacing[54] or saline loading[55]. Structural changes as a consequence of raised 
LV filling pressures include left atrial dilatation,[56] left ventricular hypertrophy,[45] 
pulmonary hypertension and right ventricle dysfunction.[57] Even in patients without any 
evidence of overt left ventricular remodelling, diffuse myocardial fibrosis may be evident 
using T1 mapping techniques with cardiac magnetic resonance imaging (CMR).[58] 
 
Raised filling pressures can be detected invasively as a raised left ventricle end-diastolic 
pressure, left atrial pressure or pulmonary capillary wedge pressure.[59] Echo surrogates for 
these and other catheter derived parameters of relaxation or stiffness are not as reliable.[60-
62] Two studies which compared diastolic function using conductance catheters against 
echocardiography concluded that tissue Doppler imaging with E/e‟ provided the best estimate 
of LV filling pressures.[60, 61] 
 
Key cellular pathways identified to affect diastolic relaxation and increase myocardial 
stiffness include abnormal calcium-handling proteins, reduced β1-adrenergic receptor 
expression, enhanced collagen deposition, collagen cross-linking, amyloid deposition and 
abnormal titin handling.[43, 48, 63] 
 
Triggers for these cellular pathways include systemic inflammation driven by co-
morbidities,[10] impaired coronary endothelial dysfunction, reactive oxidative stress, 
ischaemia and activation of the renin-angiotensin-aldosterone system.[43, 48, 63, 64] 
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1.6.2 Systolic Dysfunction 
HFpEF also used to be known as heart failure with normal systolic function. The latter 
nomenclature was deemed to be inaccurate, when it was discovered that abnormalities in 
systolic function were common in patients with HFpEF.[65] These abnormalities were 
detected using tissue Doppler and strain based imaging.[66] In a cohort of 244 patients with 
HFpEF, those patients with impairment in contractility as shown by a reduced mid-wall fibre 
shortening (as opposed to EF) experienced reduced survival.[67] This systolic dysfunction 
may be accentuated on exercise (impaired systolic reserve) and this has been shown to be 
related to a failure in decreasing end-systolic volume upon exercise thereby inhibiting the 
necessary augmentation in stroke volume.[68] Myocardial ischaemia amongst others may be 
an important cause of impairment in systolic reserve.[69] 
 
Ejection fraction as a marker of systolic function has limitations and is currently used in the 
guidelines due to the absence of a better method to diagnose HFpEF. It has a test-retest 
variability of 5-10%,[70] and may cause misclassification in a proportion of patients who 
have a measured EF close to the chosen threshold.[71]  
 
1.6.3 Ventriculo-arterial stiffening 
The ventricular pump and the vasculature work in unison to deliver blood around the body. 
EF perhaps more aptly describes ventricular-arterial coupling; EF is proportional to 
ventricular contractility and inversely proportional to afterload.[48] Arterial blood vessels 
stiffen with age and co-morbidities such as diabetes, hypertension and renal disease. To 
preserve the coupling (and EF) between the left ventricle and arterial system, the ventricle 
remodels developing hypertrophy and stiffens and hence HFpEF develops.[72, 73] 
 
Though the system is usually able to meet the body‟s needs in the resting state, it may fail 
when demands are increased. Upon exercise, the response in health is peripheral 
vasodilatation and a reduction in afterload, allowing cardiac output to increase. In HFpEF the 
reduction in afterload is not as pronounced [73] and the increased vascular stiffness 
predisposes the patient to exaggerated changes in blood pressure for relatively small changes 
in preload or afterload.[73] This sensitive relationship between preload, afterload and blood 
pressure explains why in HFpEF significant hypertension upon exercise or severe 
hypotension with over-diuresis is seen. 
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Abnormalities in the microvasculature in particular endothelial dysfunction, are also noted in 
HFpEF.[68] In a cohort of 321 patients with HFpEF, endothelial function assessed by 
reactive hyperaemia index at the fingertip level was shown to be predictive of cardiovascular 
events. [74] 
 
Recently a new paradigm for the development of HFpEF has been proposed, one in which it 
is suggested that the disease is driven by systemic inflammation caused by co-morbidities, 
which in turn, cause coronary microvascular inflammation. This reduces nitric oxide 
bioavailability, reduces protein kinase G activity and affects titin activity; all of these 
promote left ventricular stiffness and heart failure.[10] 
 
1.6.4 Chronotropic incompetence  
Cardiac output (stroke volume x heart rate) needs to increase during exercise to meet the 
metabolic needs of skeletal muscle. In HFpEF not only is the ability to increase stroke 
volume impaired due to ventricular-arterial stiffening but so is the ability to augment heart 
rate (otherwise known as chronotropic incompetence).[75] When 17 patients with HFpEF 
were exercised, they augmented their heart rate and cardiac output 40% less than 19 control 
patients without heart failure but matched for co-morbidities.[75] Others groups have also 
confirmed chronotropic incompetence as well as impaired heart rate recovery in this 
population.[76, 77] The underlying mechanisms for these blunted heart rate responses are 
believed to be abnormalities in the autonomic nervous system including reduced β-
adrenoreceptor function.[77] 
 
1.6.5 Pulmonary hypertension and right ventricular dysfunction 
Left atrial hypertension secondary to raised filling left ventricle filling pressures in HFpEF is 
common. It is frequently associated with left atrial dilatation and promotes atrial fibrillation 
(AF). This arrhythmia is associated with exercise intolerance, systemic embolism and 
increase risk of mortality. [78] AF as well as atrial hypertension is associated with elevated 
pulmonary pressures which can exert a deleterious effect on right ventricle systolic 
function.[79, 80] 
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The gold-standard method of measuring pulmonary artery pressure is invasive right heart 
catheterisation. Doppler echocardiography of tricuspid regurgitation can give a reliable 
estimate of pulmonary artery pressures and due to its non-invasive nature is more widely used 
for population screening.[81] Co-morbidities such as uncontrolled systemic hypertension, 
chronic obstructive airways disease and obstructive sleep apnoea, which are prevalent in 
HFpEF may also contribute to pulmonary hypertension. 
 
The right ventricle in HFpEF also demonstrates increased stiffness.[79] Furthermore due to 
interactions of the inter-ventricular septum systolic abnormalities in the left ventricle also 
affect the right.[79] Right ventricular dysfunction and raised pulmonary pressures have been 
shown to be associated with increased mortality and morbidity in HFpEF.[82] 
 
1.6.6 Renal dysfunction 
Chronic kidney disease is present in approximately a third of patients with HFpEF.[30] Its 
presence confers an adverse prognosis.[30, 83] It is unclear what the mechanism of renal 
dysfunction in HFpEF is and it is likely that the heart has an adverse effect on renal function 
through neurohumoral activation,[84] venous congestion[85] and medications (e.g. diuretics 
increase sympathetic nervous system activity[86]) and similarly renal dysfunction (secondary 
to co-morbidities) is likely to impact cardiac function through inflammation and 
neurohumoral activation (Figure 1.5).[10] 
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Figure 1.5: Cardio-renal interactions in heart failure. Reproduced from [83]. 
 
1.6.7 The Sympathetic Nervous System 
The sympathetic nervous system (SNS) exerts modulatory effects across all of the key organs 
implicated in HFpEF including the heart, peripheral vasculature, kidneys and peripheral 
muscle.[87, 88] The SNS has been shown to be activated in patients with HFpEF compared 
to healthy normal controls.[89-92] In humans there is some evidence to suggest a „dose-
response‟ relationship i.e. the greater the SNS activation, the worse the outcome or 
physiological performance of the patient.[90, 93]. Table 1.3 lists maladaptive effects of the 
SNS that may promote HFpEF. The corollary would be that SNS attenuation in HFpEF 
would be beneficial, which is what the main hypothesis of this thesis is testing.  
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Organ Maladaptive effects of the SNS that may promote HFpEF 
Heart Hypertrophy, Diastolic Dysfunction, Arrhythmia (especially atrial), Ischaemia, 
Chronotropic incompetence, Impaired heart rate recovery, Abnormal 
baroreceptor function 
Blood 
vessels 
Vasoconstriction, Increase afterload, Decreased arterial compliance, 
Endothelial dysfunction, Venous capacitance dysfunction,  
Kidneys Increased renin secretion, Reduced sodium excretion, Decreased renal blood 
flow, Albuminuria 
Skeletal 
Muscle 
Mismatch of blood flow to regional demand in muscle due to impaired 
vasodilatation, ergoreflex stimulation 
Table 1.3: Harmful effects of an elevated SNS in HFpEF 
 
Left ventricular hypertrophy is a precursor of heart failure regardless of ejection fraction and 
when present in heart failure is associated with a worse prognosis.[94, 95] In HFpEF, the 
typical pattern of hypertrophy is concentric though in some patients it might be eccentric or 
non-existent.[96] Animal models involving isoproterenol (non-selective β-adrenoreceptor 
agonist)[97-99] or noradrenaline infusion[100, 101] have shown that pharmacological SNS 
activation can induce left ventricular hypertrophy, diastolic dysfunction, myocardial fibrosis 
and increased myocardial stiffness with reductions in EF only being induced in those animals 
subjected to high doses. 
 
Patients with bronchial asthma who are prescribed oral beta-agonists are a unique cohort in 
whom the longitudinal effects of chronic SNS activation can be studied. In one such study, 
patients who were administered oral beta-agonists were more likely to have diastolic 
dysfunction and non-fatal heart failure events. Furthermore, withdrawal of beta-agonists led 
to improvement in diastolic echocardiogram-based parameters.[102] In patients with 
hypertension the presence of diastolic dysfunction is associated with elevated SNS 
activity.[103, 104] 
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SNS overactivity at the cardiac level increases intracellular calcium via multiple mechanisms, 
which can promote arrhythmia and substrate remodelling.[105, 106] Atrial fibrillation is the 
commonest arrhythmia, affecting up to 40% of the HFpEF population.[17, 107] The presence 
of AF with HFpEF is associated with increased mortality and hospitalisation.[108-111] 
Attenuating the SNS with renal denervation has been shown to reduce AF recurrences in 
patients with resistant hypertension undergoing catheter ablation for AF.[112] 
 
The SNS influences arterial tone and venous tone (via adrenergic neurones and circulating 
noradrenaline).[85] Its effects on the arterial system include increased afterload and blood 
pressure. However, approximately 70% of the blood volume is contained in the venous 
system.[85] Increases in sympathetic outflow to the venous system can redistribute blood 
from venous reservoirs into the circulating volume, increasing left ventricular filling pressure. 
This may explain why weight gain (due to fluid retention) is seen in less than 50% of patients 
who decompensate with pulmonary oedema.[113] Indeed in an animal model pulmonary 
oedema can be precipitated in the presence of normal contracting and relaxing ventricles in 
response to smaller volume loads when arterial baroreflexes are eliminated.[114] 
 
It has been hypothesised that therapies that reduce SNS activity may be of benefit in patients 
with HFpEF.  Beta-blockers, renin-angiotensin-aldosterone receptor blockers and digoxin can 
attenuate some of the harmful effects of the SNS though it remains unclear what role these 
drugs may have in patients with HFpEF as the currently available trial evidence is limited as 
discussed in a subsequent section.  
 
1.7 Treatment Targets and Clinical Trials in HFpEF 
The observation that the final clinical picture of raised left ventricular filling pressure, 
pulmonary oedema and peripheral oedema is common to both HFpEF and HFrEF, led 
researchers to examine drugs that had already been shown to make a valuable prognostic 
impact for patients with HFrEF in HFpEF.[115] These include: 
 
1. Inhibitors of the renin-angiotensin-aldosterone system (RAAS). When permanently 
activated the RAAS can drive collagen deposition, myocardial fibrosis, hypertension, 
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endothelial dysfunction, vascular and cardiac stiffening, which are important features 
of HFpEF.[116-118]. 
 
2. Beta-adrenoreceptor blockers (beta-blockers). The rationale for using beta-blockers in 
HFpEF include: heart rate control to reduce myocardial ischaemia especially in 
patients with concomitant coronary artery disease or left ventricular hypertrophy;[119, 
120] inhibition of renin, which in animal models is associated with a reduction in 
myocardial fibrosis and improvement in diastolic function;[121] and attenuation of 
the harmful effects of adrenergic overactivity and in particular the associated risk of 
atrial arrhythmias.[78, 122] Other drugs such as digoxin and ivadrabine that can lower 
heart rate have also been evaluated. 
 
Recently, researchers have targeted other pathways that previously have not been shown to 
make a prognostic impact in the HFrEF population: 
 
3. Phosphodiesterase-5A (PDE5A) inhibition. The potential benefits of this through 
enhanced cyclic guanosine monophosphate (cGMP) and protein kinase G (PKG) 
activity are found at the level of the myocardium (reverses maladaptive fibrosis and 
left ventricular hypertrophy, improves diastolic function), vasculature (reduces 
pulmonary and systemic vascular resistance, improves endothelial function) and 
neurohumoral activity (reduces sympathetic overactivity, enhances natriuretic peptide 
function).[43, 123] 
 
4. Angiotensin receptor neprilysin inhibitor (ARNI). Neprilysin degrades biologically 
active natriuretic peptides.[124] These peptides may have a beneficial effect in heart 
failure through: enhanced natriuresis, vasodilation and sympatholytic effects.[125] 
Natriuretic peptides have also been shown to increase myocardial cGMP which can 
reduce myocardial hypertrophy and improve relaxation, which are likely to be of 
benefit in the HFpEF population. As neprilysin also contributes to the breakdown of 
angiotensin, this drug is combined with an angiotensin receptor blocker (angiotensin 
converting enzyme inhibitors are not used in combination due to the increased risk of 
angioedema).[126, 127] 
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I will summarise the key randomised controlled trials involving the above four pathways. An 
important distinction to be made is between phase II studies which aim to investigate 
mechanisms and demonstrate safety and phase III studies which are a magnitude larger and 
seek to demonstrate improvement in hard outcomes such as mortality and hospitalisations. 
 
1.8 Renin-angiotensin system blockade 
1.8.1 Phase II studies 
In an open-label randomised-controlled trial, enalapril compared to placebo was shown to 
improve New York Heart Association (NYHA) class, treadmill exercise duration, left 
ventricular mass and diastolic function at 3 months in 22 patients with heart failure secondary 
to previous Q-wave myocardial infarctions albeit with an EF>50%.[128] In a double-blind, 
placebo-controlled, crossover trial of patients with shortness of breath on exertion, EF>50% 
and an exaggerated blood pressure response on exercise, two weeks of losartan improved 
heart failure questionnaire scores as well and reduced peak blood pressure on exercise.[129] 
 
1.8.2 Phase III studies 
There are three double-blind, multicentre, randomised, placebo-controlled phase III trials. 
 
The Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity 
(CHARM) - Preserved study randomised 3023 patients to either candesartan or placebo and 
followed them for a median of 37 months.[130] To be eligible patients had to be older than 
18 years of age, have symptomatic heart failure, EF>40% and have been previously admitted 
to hospital for a cardiac reason. The combined primary endpoints of cardiovascular death or 
unplanned heart failure hospitalisation were not met. When the primary end-points were 
considered separately, patients who received candesartan did experience less heart failure 
hospitalisations. Criticisms of the trial include: 1) The majority (56%) of the recruited 
patients had heart failure that was ischaemic in origin with eccentric remodelling, which 
suggested that the patients were more likely to have had HFrEF or have recovered from 
previous HFrEF as opposed to HFpEF. 2) In the echo sub-study of CHARM-preserved (10% 
of the trial population), one-third did not have evidence of diastolic dysfunction, which led 
many to question whether the recruited patients even had heart failure.[131] 3) 20% of 
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patients were already taking angiotensin converting enzyme inhibitors at randomisation, 
which may have diluted any study drug effect. 
 
The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) trial enrolled 850 
patients who were 70 years of age or older with clinical symptoms of heart failure, an 
EF>40% derived from wall motion index and evidence of diastolic dysfunction (any two of: 
dilated left atrium (diameter>40mm), left ventricular hypertrophy (wall thickness ≥12mm), 
atrial fibrillation and abnormal Doppler parameters (E/A ratio <0.5, deceleration time 
>280ms or isovolumic relaxation time >105ms).[132] Importantly they sought to recruit 
patients who were older and also had objective diastolic dysfunction to better capture an 
HFpEF population. However, due to slow recruitment, a lower than anticipated event rate and 
high-rate of cessation of blinded therapy with either open-label angiotensin converting 
enzyme-inhibitor (ACEi) or intolerance (40% at 18 months) the trial steering committee 
recommended early cessation of the trial. The primary endpoint, all-cause mortality or heart 
failure hospitalisation was not met. However, due to the trial circumstances, re-analysis was 
performed for events during the first year of follow-up only, when 90% of treated patients 
were still taking perindopril. With this different approach, there was a signal in favour of 
perindopril (HR 0.69; 95% CI 0.47-1.01, p=0.055) for the primary outcome. When the 
outcome of cardiovascular death or heart failure hospitalisation (primary outcome of 
CHARM-preserved) was tested at one year, this was shown to be positive in favour of 
perindopril (HR 0.62; 95% CI 0.42-0.92, p=0.018). There was also an improvement seen in 
the six minute corridor test by 14 metres.  
 
The Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) 
examined the role of irbesartan in 4128 patients with an EF≥45%.[133] As refining criteria, 
patients either had to have had a heart failure hospitalisation in the previous 6 months or be 
NYHA class III/ IV with corroborative evidence which included: pulmonary congestion on 
chest radiography, left ventricular hypertrophy, left atrial enlargement or left bundle branch 
block. The primary outcome, all-cause mortality or cardiac hospitalisation, was not met. The 
echo sub-study suggested that one-third of patients did not have diastolic heart failure and 
only 15% of patients had moderate or greater left atrial dilatation, suggesting that an 
advanced phenotype of HFpEF was not recruited to the trial.[134] Another key explanatory 
factor for the neutral results is that there was a high use of other RAAS system blocking 
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drugs at baseline during the study including ACEi (25%) and spironolactone (15%). By the 
end of the study these proportions had increased to 40% and 28%, which may have masked 
any benefit from irbesartan. 
 
Secondary analysis of I-PRESERVE offered further insights into HFpEF. First, though the 
study drug had no effect on natriuretic peptide level compared to placebo, the trial 
confidently showed that NT-pro BNP was a strong predictor of prognosis.[135] Second, 
worsening renal function (serum creatinine increase by ≥ 26.5 umol/l and ≥25% of baseline) 
was twice as common with irbesartan as opposed to placebo (8% vs 4%).[136] Those patients 
prescribed irbesartan who suffered worsening renal function were more likely to experience 
the primary endpoint, which is in stark contrast to patients with HFrEF, in whom worsening 
renal function secondary to ACEi is not associated with worse outcome.[137] This difference 
is difficult to reconcile and suggest that benefits of RAAS blockade are counteracted by the 
harmful effects of deteriorating renal function.[138] 
 
1.9 Aldosterone receptor blockade 
1.9.1 Phase II studies 
The Randomised Aldosterone AntagonisM in heart failure with Preserved Ejection Fraction 
(RAAM-PEF) trial recruited 44 patients with clinical heart failure, EF≥50% and a BNP level 
≥100pg/ml.[139] Six months of eplerenone did not improve the six minute walk distance 
(primary end point), heart failure symptom score, left ventricular mass or left atrial volume. 
The study drug did, however, reduce E/e‟ and lead to favourable changes in biomarkers of 
collagen turnover. 
 
This was followed by a 422 patient study which investigated the role of spironolactone in 
HFpEF (Aldo-DHF).[140] Patients were eligible for the study if they had symptomatic heart 
failure, EF≥50%, mild diastolic dysfunction or atrial fibrillation and a peak VO2 of ≤ 
25ml/kg/min. Treatment with spironolactone was associated with a significant decrease in 
E/e‟, left ventricular mass and N-terminal prohormone of B-type natriuretic peptide 
(NTproBNP) but there was not effect on peak VO2 or symptom score. Although the study 
was neutral as it did not meet its primary endpoint (improvement in E/e‟ and peak VO2) it 
did provide encouraging signals for spironolactone. 
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1.9.2 Phase III study 
The Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonisT 
(TOPCAT) trial is the most recent outcome study published in the HFpEF literature.[141] 
3445 patients were randomised. Patients had to have symptoms and signs of heart failure, an 
EF≥45% and either a heart failure hospitalisation in the previous 12 months or a BNP≥ 100 
pg/ml (NTproBNP≥ 360pg/ml). The primary outcome was a composite of cardiovascular 
death, or aborted cardiac arrest or heart failure hospitalisation. The trial was neutral for the 
primary outcome. However, there were several interesting findings: 1) Spironolactone did 
reduce heart failure hospitalisation in HFpEF patients (HR: 0.83, 95% CI 0.69–0.99, p=0.04). 
2) When the primary outcome was re-analysed depending on whether the patient was 
recruited under recent heart failure hospitalisation or elevated natriuretic peptide criteria, 
spironolactone was effective in the latter group. Geographic variation in HFpEF diagnosis 
and phenotype has been offered as an explanation; the patients recruited under the 
hospitalisation criteria were predominately from Russia and Georgia and these patients also 
had a lower event rate. 3) Similar to many of the previous studies of this population, the 
recruited patients were not at the highest end of the risk spectrum. From the echo sub-study 
(n=935), left atrial enlargement was present in only 53% of patients and 44% of patients did 
not have diastolic dysfunction.[44] 
 
1.10 Beta-blockers 
1.10.1 Phase II studies 
The Swedish Doppler echocardiographic study (SWEDIC) recruited 113 patients with heart 
failure, EF>45% and Doppler evidence of diastolic dysfunction. The investigators excluded 
patients with evidence of significant myocardial infarction as identified by akinesia of two or 
more myocardial segments on echocardiography. Carvedilol was the investigational drug. 
The primary endpoint was change at 6 months in four Doppler markers of diastolic function. 
The study was neutral but in a secondary analysis patients with a resting heart rate greater 
than 71 beats per minute experienced a greater improvement in E:A with carvedilol compared 
to placebo. 
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The Effects of Long-term Administration of Nebivolol on the clinical symptoms, exercise 
capacity, and left ventricular function of patients with Diastolic Dysfunction (ELANDD) 
study reported in 116 patients with symptomatic HFpEF (EF>45%, non-dilated left ventricle, 
and echo based features of diastolic dysfunction) that placebo improved six minute walk test 
distance more than nebivolol, though there was no difference between the groups with respect 
to peak oxygen extraction (peak VO2).[142] Nebivolol reduced peak exercise blood pressure 
and heart rate. The authors suggested that lowering heart rate in HFpEF, lowers peak VO2 
and hence may be undesirable. The patients recruited to ELANDD were on the mild end of 
the heart failure spectrum with median NT-pro BNP of 131 pg/ml and 78% of the recruited 
patients had NYHA II symptoms, which suggests that they may not have been sick enough to 
benefit from the investigational drug. 
 
1.10.2 Phase III studies 
The Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors 
with heart failure (SENIORS) randomised 2111 patients (active drug was nebivolol) who 
either had been admitted with heart failure decompensation or who had a documented 
EF≤35%.[143] 643 patients from this study had an EF≥40% and in this smaller subgroup the 
effect of nebivolol on the primary outcome of all-cause mortality or cardiovascular 
hospitalisation was not different to those patients with an EF≤35%. The sub-group analysis 
by EF was not powered for the primary end-point. A further sub-study of the SENIORS 
cohort reported that the beneficial effects of nebivolol on the primary outcome were not seen 
in patients with atrial fibrillation at randomisation and furthermore outcomes in the AF cohort 
were not dependent on EF.[144] 
 
In another study, 158 patients with ischaemic heart disease, an EF≥40% with symptoms and 
clinical features of heart failure, propranolol reduced all-cause mortality (HR 0.65; 95% CI 
0.44-0.96, p=0.03), regressed left ventricular hypertrophy and improved left ventricular 
ejection fraction.[145] Propranolol was not tolerated by 14% of the study patients. 
 
Finally, carvedilol was investigated in the Japanese Diastolic Heart Failure (J-DHF) 
study.[107] To be eligible patients had to have a clinical diagnosis of heart failure with an 
EF>40%. The trial was not blinded and used a prospective randomised open blinded-endpoint 
design. The primary endpoint was time to cardiovascular death or first heart failure 
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hospitalisation. 800 patients were required for the study to have 80% power to detect a 20% 
risk reduction. However, recruitment was slow and the trial was stopped after 5 years at 
which stage only 245 patients had been randomised. The trial results were neutral. Only 22% 
of the patients reached the target dose of carvedilol at 20mg/day. A post-hoc analysis showed 
that in patients who achieved a dose of 7.5mg/day or higher (the median dose), the incidence 
of the composite outcome was lower compared to control (HR 0.54; 95% CI 0.30-0.96, 
p=0.036).  
 
1.11 Other drugs that can lower heart rate 
Three other drugs that can reduce heart rate have been evaluated in the HFpEF cohort: non-
dihydropyridine calcium channel blockers, ivabradine and digoxin. In addition calcium 
channel blockers may also exert beneficial blood pressure lowering effects and digoxin may 
have favourable effects on the neurohormonal profile in heart failure.[146] 
 
The first two drugs have been tested in only small mechanistic studies. Verapamil was shown 
in two trials one involving 20 men[147] and another 15 elderly men with HFpEF[148] to 
improve a composite heart failure score and exercise capacity. In a randomised control trial 
of 61 patients with HFpEF, seven days of ivabradine was associated with an improvement in 
exercise capacity, peak VO2 and E/e‟.[149] 
 
The Digitalis Investigation Group (DIG) ancillary trial found digoxin not to be effective in 
reducing the risk of heart failure mortality or heart failure hospitalisation in 988 patients with 
HFpEF (EF>45%) and sinus rhythm.[150] 
 
It is unlikely that heart rate lowering will benefit all HFpEF patients as shown by the neutral 
results of the larger trials involving digoxin and beta-blockers. Mechanistically, it is 
reasonable to hypothesise that in those patients with resting bradycardia or chronotropic 
incompetence, further heart rate lowering may reduce cardiac reserve and exercise 
capacity.[43] Another group of patients who might not benefit are those with advanced 
HFpEF with stiff ventricles and restrictive filling who rely on heart rate augmentation as to 
increase cardiac output on exertion.[151] 
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1.12 Phosphodiesterase-5A inhibition 
1.12.1 Phase II studies 
Guazzi and colleagues undertook a double-blind placebo-controlled randomised trial in 44 
patients with HFpEF (EF≥50%, estimated systolic pulmonary artery pressure≥40mmHg, 
sinus rhythm).[152] Compared to placebo, one year of sildenafil reduced pulmonary vascular 
resistance, pulmonary artery pressure, pulmonary artery wedge pressure, left and right 
ventricular wall thickness as well as Doppler based parameters of diastolic dysfunction. This 
study gave a clear signal towards the value of PDE5A inhibition in HFpEF. 
 
A subsequent larger study (n=216) was, however, neutral.[153] Importantly, this study had 
different inclusion criteria and hence, may have recruited a different phenotype of HFpEF 
that perhaps was not best matched to the study drug.[151] They did not require their patients 
to have features of pulmonary hypertension due to left sided heart disease. Furthermore, their 
primary end-point was peak VO2 upon exercise rather than pulmonary artery pressure used 
by the previous paper. This may not have been an ideal endpoint as performance might have 
been affected by the high prevalence of cardiac and non-cardiac co-morbidities that are so 
common in HFpEF. There was also some evidence of harm from sildenafil, in particular with 
respect to renal function.  
 
1.13 Angiotensin receptor neprilysin inhibitor 
1.13.1 Phase II study 
The Prospective comparison of ARNI (angiotensin receptor neprilysin inhibitor) with ARB 
(angiotensin receptor blocker) on Management Of heart failUre with preserved ejectioN 
fracTion (PARAMOUNT) trial reported data on 266 patients with signs and symptoms of 
heart failure, who had an EF≥ 45%, a NT-proBNP>400 pg/ml, controlled blood pressure and 
were on treatment with a diuretic.[154] The primary endpoint was change in NT-proBNP at 
12 weeks. Those patients who received the investigational drug (ARNI and valsartan) had a 
significant reduction in NT-proBNP compared to the control arm (valsartan only), however, 
the change did not remain statistically significant at 36 weeks. These changes were also 
mirrored by improvements in blood pressure and left atrial volume at 36 weeks.[154] There 
was a greater increase in albuminuria in the active arm compared to the control arm at 36 
weeks. A phase III study is currently on-going. 
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1.14 Summary 
There are currently no medications that have been convincingly proven in outcome studies to 
improve the composite outcome time to death or hospitalisation in HFpEF (Figure 1.6). There 
is a suggestion that renin-angiotensin-aldosterone blockade may reduce heart failure 
hospitalisation. Trial-related factors have strongly contributed to the totality of neutral studies 
in this field. Moving forward, the most important lesson learned from all of the phase II and 
III studies performed is the importance of successfully targeting the right pathway, choosing 
the right patient to study, selecting the right endpoints to test and designing the right 
study.[155] The SNS may be an appropriate target that has not yet been adequately 
investigated in HFpEF. 
 
 
Figure 1.6: Forest plot summary of the hazard ratios with 95% confidence intervals of 
the primary endpoint from HFpEF outcome trials.  
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2 Background: Renal Denervation 
 
2.1 The Procedure 
Renal denervation (RDT) is a novel percutaneous transcatheter technique that seeks to 
diminish renal efferent and afferent SNS activity. The procedure was first performed in man 
in 2007 as part of a pilot study evaluating RDT in patients with resistant hypertension.[156] 
The intervention relies on the anatomical proximity of the renal sympathetic nerves to the 
renal artery lumen (initial cadaveric histological studies suggested that over 95% of the 
nerves were found within 2mm of the artery lumen), which makes them amenable to ablation 
therapy.[157] However, a subsequent and perhaps more comprehensive study of human renal 
nerve histology suggested that over 90% of nerves were found within 6mm of the artery 
lumen (i.e. three times the distance that was previously assumed).[158] 
 
The majority (>90%) of the experience in RDT is with the Symplicity Flex (Medtronic Inc, 
USA) single electrode catheter (Table 2.1). There are now five other catheters with the 
Conformité Européene (CE) mark and hence available for use in Europe ( Table 2.2).[159, 
160]  
 
 
Table 2.1:Summary of the published renal denervation trials including number of trials 
published, number of patients denervated using different catheters and reported 
complications. 
a
The OneShot denervation system is no longer produced. EP- cardiac 
electrophysiological study catheter. Renal artery complications includes dissection and 
stenosis; Renal function complications includes a greater than 50% deterioration in renal 
function or new end stage renal failure; Femoral artery complications includes 
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pseudoaneurysm or significant haematoma. Reproduced from [160] under Creative Commons 
Attribution licence.  
 
 
Table 2.2: Currently available CE marked renal denervation catheters.
a
 Minimum 
estimated time of RF delivery. 
b
 There is also a 5Fr version of Paradise™ called Radiance™ 
that may be used via the radial artery. RF- radiofrequency; US- ultrasound; CE- Conformité 
Européene. Reproduced from [160] under Creative Commons Attribution licence.   
 
RDT is generally performed in a fit-for-purpose cardiac catheterisation laboratory. Ablation 
of the renal nerves elicits a pain response and hence analgesia and sedation are mandatory 
and may include intravenous opioid, midazolam and/or paracetamol. Intra-arterial heparin is 
used to maintain an activated clotting time (ACT) >250 seconds during the procedure. 
Endovascular femoral access is gained using Seldinger technique, maintained with a femoral 
sheath, and later if appropriate, the arterial access point is sealed with a vascular closure 
device. Access to the renal artery is obtained using an 80 cm 6 Fr guide catheter (RDC or 
IMA curve). Occasionally the use of a 0.014 inch guide wire can facilitate the subsequent 
advancement of the denervation catheter. In the original described procedure (using the  
Symplicity Flex™) the catheter is then advanced and positioned in the most distal aspect of 
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the renal artery proximal to bifurcations, good vessel wall contact is obtained by deflecting 
the electrode tip and confirmed by demonstration of an impedance of 250-300 Ohms on the 
power generator. Using a dedicated low intensity radiofrequency (RF) generator, 4-6 discrete 
ablations lasting 2 min at a maximum of 8 watts are delivered to each renal artery (left and 
right); after each RF ablation the catheter is pulled back manually 5 mm, and the catheter is 
rotated 90 degrees to achieve circumferential coverage ( Figure 2.1). This controlled spiral 
movement of the catheter is expected to avoid circumferential applications of energy in the 
same renal artery segment although a circumferential denervation is still achieved.  Catheter 
tip temperature and impedance are constantly monitored during ablation and RF energy 
delivery is regulated according to a predetermined algorithm, i.e. the generator turns off 
ablation if the temperature is too high (catheter too aggressively turned against the wall) or if 
the impedance is too low (insufficient vessel wall contact). The technique is slightly modified 
depending on the type of denervation catheter that is used.   
 
 Figure 2.1: The renal denervation therapy procedure. Denervation catheter is positioned 
against the renal artery wall using fluoroscopy. A series of 4-6 ablations are performed in a 
helical pattern 5mm apart. Reproduced from [161] under Creative Commons Attribution 
licence.  
 
Anticipated complications of RDT include those common to any cardiovascular 
interventional procedure (arterial access site complications, allergy, infection) and those 
specific to the RDT procedure (renal artery damage: dissection, spasm, perforation, stenosis, 
thrombus formation and embolism). The majority of studies have reported the incidence of 
acute complications to be low, however, there has been limited systematic imaging for renal 
artery stenosis at appropriate time points after the procedure and hence the true incidence of 
this may not be fully appreciated.[162] Finally, there is also a possibility of sympathetic 
nerve regrowth, which has been shown in animal models [163, 164] and hence, the need for a 
repeat procedure. 
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2.2 Assessment of the effect of renal denervation on the SNS 
The biggest limitation of RDT in man is that there is no marker of procedural success, which 
is pivotal to determining if a non-response is related to inadequate ablation or inadequate 
response to successful ablation.[161] An impedance drop of greater than 10% during an 
ablation was considered a marker of a successful ablation but in reality only indicates a 
successful energy delivery and does not confirm or quantify the successful damage of target 
nerves.[165] Indirect methods have been proposed to assess the degree of renal nerve damage 
during the procedure. A promising technique assesses the effect of low frequency electrical 
stimuli upon haemodynamic measurements before and after RDT, with blunted increases in 
heart rate and blood pressure expected after successful denervation.[112, 166-168]  
 
Another approach would be to assess the effect of RDT on the autonomic nervous system. 
Unfortunately, there are no „gold-standard‟ techniques for assessing the SNS, and each 
available one offers complementary information to the other.[169] Figure 2.2, summarises the 
different available techniques. Analysis of heart rate and blood pressure responses are widely 
available and non-invasive. The balance between the SNS, the parasympathetic nervous 
system (PNS) as well as non-autonomic factors such as temperature determines the actual 
heart rate.[170] Generally, sympathetic activation is associated with increased heart rate.  
 
 
Figure 2.2: Different techniques to assess sympathetic nerve activity. Reproduced from 
[169]. HRV- heart rate variability; BRS- baroreceptor sensitivity; mIBG- 
123
I-meta-
iodobenzylguanidine; PET- positron emission tomography. 
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Heart rate variability (HRV) is a more sophisticated analysis of heart rate and involves 
examining successive inter-beat (or RR) intervals with various mathematical tools. 
Traditionally, five-minute or 24 hour recordings are analysed. Time domain analyses are 
commonly performed on 24 hour data, whereas frequency domain analyses are performed on 
five-minute data. The limitations of these techniques are the high inter- and intra- patient 
variability and hence despite being used as a research tool for over 30 years, no parameters of 
HRV are currently promoted in clinical guidelines. Furthermore their role in heart failure 
research is limited as it is currently unclear how to interpret RR interval variability in patients 
who have irregular heart rates such as those in atrial fibrillation or artificially regular heart 
rates following pacing. Baroreceptor sensitivity (BRS) can also be evaluated by analysing 
beat-to-beat changes in blood pressure and RR-intervals however, it shares the same 
limitations in heart failure as with the HRV techniques.[171]  
 
The other non-invasive modality for assessing the SNS is radiotracer imaging of sympathetic 
nerve terminals, using radiolabelled noradrenaline analogues with either single photon 
emission tomography (SPECT) or positron emission tomography (PET).[169] The main 
neurotransmitter of the cardiac SNS is noradrenaline. The majority of noradrenaline released 
into the synaptic cleft is reabsorbed by the presynaptic nerve using the uptake-1 mechanism. 
Some is taken up by the effector cell (e.g. cardiomyocytes) using the uptake-2 mechanism 
and the remainder „washes out‟ into the circulation. 
 
SPECT is more widely available and cheaper than PET, though PET has better spatial 
resolution.[172] Both expose the patient to radiation. SPECT imaging of the cardiac 
sympathetic nerves uses 
123
I-meta-iodobenzylguanidine (mIBG). It has a strong affinity for 
the uptake-1 receptor in the pre-synaptic neurone and is relatively resistant to degradation. 
Three semi-quantitative parameters are routinely assessed during mIBG imaging: heart-to-
mediastinum ratio (HMR), washout and defect scores. mIBG tracer images reflect 
catecholamine storage in cardiac sympathetic nerve fibres. The HMR compares the mean 
count per pixel, within the cardiac area of interest, to that of the mediastinum (a suitable 
control), thereby allowing an estimate of neuronal activity. In contrast, myocardial washout 
compares cardiac pixel counts early (15 min) with late counts (4 h) after tracer administration 
and is a marker of neuronal integrity.[169] The effects of RDT on cardiac SNS as assessed by 
mIBG scintigraphy have not been published. 
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The other two techniques are invasive and can give organ specific information. Noradrenaline 
spillover requires organ specific paired samples (e.g. for cardiac spillover, blood is 
withdrawn from the coronary sinus and aorta; for renal spillover from the renal veins and 
aorta), whilst radiolabelled noradrenaline is peripherally infused.[169] There are very few 
centres around the world, which have the skills and technology to perform this reliably. RDT 
was shown to reduce renal noradrenaline spillover in a subset of ten patients in the initial 
proof-of-concept study in resistant hypertension.[156]  
 
It is easier to assay noradrenaline directly in the blood or urine, however, the measurement 
does not give a reliable assessment of sympathetic nerve firing as only 20% of the 
noradrenaline released at the synaptic cleft enters the circulation and only 2% is excreted into 
the urine.[173, 174]  
 
The final technique involves the insertion of a metal electrode into a peripheral sympathetic 
nerve (usually the peroneal) and is known as muscle sympathetic nerve activity (MSNA). 
This allows direct quantification of the rate of sympathetic nerve firing. MSNA estimates 
sympathetic outflow to the muscle and hence, does not given information about the heart or 
the kidneys, which in cardiovascular disease are of greater importance. MSNA is very 
operator dependent and there are only a few centres around the world that are reliably able to 
perform this technique. Unsurprisingly, reports of MSNA before and after RDT are scarce 
and what data is available is contradictory.[175-178] 
 
2.3 Rationale of Renal Denervation Therapy in Resistant Hypertension 
Excessive renal sympathetic nerve activity is implicated with induction and persistence of 
hypertension.[176, 179] In particular, efferent nerves to the kidneys, when stimulated have 
been shown to induce salt and water retention, renin secretion with subsequent activation of 
the renin-aldosterone-angiotensin system and reduce renal blood flow.[180, 181] 
Furthermore, the afferent nerves provide a feedback loop to the central nervous system, 
which can enhance sympathetic outflow to other organs in the body including the 
kidneys.[181] The renal nerves seem to be a logical target in resistant hypertension and these 
were shown to be of value in multiple preclinical studies.[166, 181-185] 
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Conceptually, RDT is less of a paradigm shift and more of a re-invention of a previously 
performed surgical procedure. Before the advent of the first effective and safe oral anti anti-
hypertensive agents in the 1950s,[159] patients with malignant hypertension (characterised 
by excessive blood pressure and end-organ damage, e.g. papilledema) would not survive 
more than five years.[186] Within this context, physicians and patients alike were keen to try 
any treatment strategy that might improve upon this grave prognosis. In 1923, Breuning was 
reported to have performed the first surgical sympathectomy for malignant 
hypertension.[159] The technique involved non-specific thoraco-lumbar ganglionectomy of 
the sympathetic chain including those to the kidneys as well as across several other organs. 
The results of these operations were variable. First, not all patients survived the operation and 
of those that did not everyone benefited from a blood pressure reduction. However, in the 
half that did respond, the effect was usually dramatic, immediate and associated with a better 
prognosis.[187, 188] Morbidity associated with the procedure was high, with patients 
commonly experiencing debilitating orthostatic hypotension, erectile dysfunction and 
incontinence.[187] Unsurprisingly, once modern anti-hypertensive agents were introduced, 
these surgical procedures were largely abandoned.[189] 
 
Further corroborative evidence for surgical renal sympathectomy is provided from the renal 
transplant medicine literature. End-stage renal failure is a condition associated with SNS 
activation and difficult to treat hypertension. In select patients who receive a renal allograft, 
nephrectomy of their native kidneys (which involves cutting through the renal sympathetic 
nerves) reduces their SNS activity, controls blood pressure, regresses left ventricular 
hypertrophy and improves blood flow through the allograft.[190-192] 
 
2.4 Resistance to Anti-hypertensive Drugs 
In the current era, first line pharmacological management of hypertension include any 
combination of: ACEi/ARB, calcium channel blocker and/or a diuretic.[193] Patients who 
remain uncontrolled on these agents could have add-on therapy with aldosterone receptor 
antagonists, adrenoreceptor blockers or centrally acting anti-hypertensives. Approximately, 
10% of the hypertension population are deemed „resistant‟ which is defined as having a blood 
pressure >140/90mmHg despite being on at least three first-line antihypertensive agents at 
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maximally tolerated doses (one of them a diuretic).[194] Before labelling a patient as having 
resistant hypertension one must exclude poor compliance to medications (a grossly 
underestimated phenomenon), secondary causes of hypertension such as hyperaldosteronism 
or renovascular disease or white coat hypertension.[193] This difficult-to-treat group have 
recently been targeted by trialists seeking to evaluate novel devices (RDT is one of these) that 
target the SNS.[169] 
 
2.5 Renal Denervation Therapy: Effect on Blood Pressure 
SYMPLICITY-HTN 1 study was a proof of concept open label study that recruited 50 
patients with resistant hypertension (defined as patients with an office systolic blood pressure 
>160mmHg, despite being prescribed three different classes of blood pressure lowering 
agents).[156] Five of the patients did not receive RDT due to inappropriate renal artery 
anatomy. In the 45 patients that did receive the treatment, an average reduction in office 
blood pressure of 24/11 mmHg was seen at six months.[156] Importantly, there were no 
signals to suggest an excessive risk of harm from the procedure. 
 
The pilot study was followed by a larger randomised open-controlled trial (n=106), 
SYMPLICITY HTN-2.[195] RDT was shown to reduce office blood pressure by 33/11 
mmHg compared to control and once again without any significant safety concerns. The 
results of these trials captured the imagination and minds of cardiologists and hypertension 
specialists alike. Multiple studies were since published, the meta-analyses of which estimated 
a 30mmHg reduction in blood pressure to be attributable to RDT.[196-198] However, an 
important limitation of these trials was that they did have design flaws which exposed them 
to bias: at the time of writing only two trials had gold standard design, i.e. were double-blind, 
sham-controlled, randomised trials that used ambulatory monitoring to define inclusion and 
assess treatment success.[199, 200] 
 
Howard and colleagues had predicted that should a gold-standard design be adopted for the 
investigation of RDT in resistant hypertension then a more modest effect size of 5-10mmHg 
might be uncovered.[196, 201, 202] They achieved this by reviewing the data from 20 
clinical trials of RDT and quantifying the effect of three key biases on blood pressure 
reduction (Figure 2.3): 
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1. Big day bias, which is also known as regression to the mean. This might occur if the 
study inclusion criteria require the participant‟s blood pressure to be above a certain 
threshold. This requirement is likely to preferentially select individuals whose blood 
pressure is above their true average on the day of assessment compared to those who are 
running below their true average. Hence, on follow-up there is a statistical expectation 
that the blood pressure will fall upon repeat measurement even without any treatment. A 
randomly chosen control arm can be used to adjust for this error. 
 
2. Check-once-more bias is a form of observer error. It refers to the temptation to remeasure 
a value that seems inconsistent with expectation, applying a routine practice in daily 
office work. An example during the course of a double-blind hypertension trial might be 
re-checking a blood pressure reading above the measurement at the time of enrolment 
driven by the knowledge that regardless of which study arm the patients is in, neither is 
receiving blood pressure elevating therapy. Ambulatory blood pressure monitoring is 
invaluable in reducing this type of error. 
 
3. I-will-take-it-now bias is an improvement in compliance during the course of the study. 
Patient partaking in an interventional trial regularly meet doctors and nurses, making 
them aware of the gravity of uncontrolled hypertension and importance of adherence with 
medications. The effect of this cannot be neutralised but may be controlled for by 
blinding the patients to the intervention. 
 
Unexpectedly, the two double-blind, sham-controlled randomised controlled trials using RDT 
for blood pressure control were both neutral (both published during the course of this thesis). 
SYMPLICITY HTN-3 was the largest and involved 535 patients[199]. A significant drop of 
14mmHg was noted in the denervation arm, however, this was not statistically different to the 
11.7mmHg drop seen in the sham-control arm. Potential reasons for the overall neutral results 
are explored further in a later chapter but may be related to ineffective denervation or trial 
related factors.[161] The second smaller study recruited 71 patients with milder resistant 
hypertension (mean day-time ambulatory blood pressure: 135-149 mmHg).[200] The study 
employed only three operators to perform the RDT, each having performed at least 20 
procedures previously. The study failed to meet it primary endpoint: change in systolic 
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24hour ambulatory systolic blood pressure at six months. However, when a per-protocol 
analysis was performed there was a significant difference (RDT (n=22): -9.5 mmHg [95% CI, 
-13.1, -5.9]; sham (n=29): -3.2 mmHg [95% CI, -6.1, -0.3]; p=0.007).[200]  
 
 
 
 
Figure 2.3: The influence of bias on blood pressure responses in renal denervation 
trials. Reproduced from [202]. 
 
2.6 Non-Blood Pressure Effects in the Resistant Hypertension population 
Heightened SNS activity is implicated in many cardiovascular disease processes and not just 
resistant hypertension. Therefore, it is conceivable that RDT may have a wider effect in 
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patients beyond blood pressure reduction. Researchers have explored the effects of RDT on 
cardiac, renal and vascular remodelling in man. I have summarised some of the key findings 
below, however, it is important to acknowledge that all of these trials are subject to the same 
biases as the initial studies in hypertension.  
 
2.6.1 Sympatholytic 
Hering and colleagues reported on the effect of RDT on 35 patients with resistant 
hypertension. They found that RDT reduced office blood pressure as well as MSNA.[203] 
This suggests that RDT has an effect not only on local renal physiology by affecting the 
afferent nerves but also sympathetic outflow from the central nervous system through the 
renal efferents. Furthermore, this data provides some supporting evidence that renal re-
innervation is not an important feature in humans who have undergone RDT. This finding is 
at odds with the animal data, in which function and anatomical renal nerve reinnervation was 
demonstrated at 11 months.[164] 
 
In a cohort of 14 patients, there was an improvement in time and frequency domain 
parameters of heart rate variability at three months compared to baseline following 
RDT.[204] The authors interpreted their findings as a reduction in overall sympathetic tone to 
the heart. In a smaller uncontrolled study of 12 patients scheduled to undergo RDT for 
resistant hypertension, no changes in blood pressure, heart rate, MSNA, heart rate variability, 
blood pressure variability or baroreceptor function were noted.[175] This study recruited 
patients with milder hypertension with mild SNS activation at baseline, which may have 
contributed to their neutral findings. In another small study of 7 patients, RDT did not reduce 
MSNA but did improve baroreceptor function at one and six months.[182, 195] Another 
group, just performed BRS analysis prior to RDT in patients with resistant hypertension and 
found this measure, when depressed to ≤ 0.62 ms/mmHg, identified patients with resistant 
hypertension who might benefit from RDT.[205] 
 
Ten patients from the original SYMPLICITY-1 pilot study had renal noradrenaline levels 
checked using the spillover technique both at baseline and within a month of the procedure. 
On average there was a mean reduction of 47% in spillover.[156] 
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2.6.2 Humoral remodelling 
In several small studies reductions in NT-pro BNP, aldosterone and noradrenaline were 
observed after RDT.[206-208] Plasma renin activity does not seem to be demonstrably 
affected.[207, 208] Circulating biomarkers of inflammation (high-sensitivity C-reactive 
protein and interleukin-6) are reduced post RDT suggesting an improvement (reduction) in 
vascular inflammation.[209] 
 
2.6.3 Cardiac Remodelling 
Using echocardiography, a reduction in left ventricular mass index and improvement in 
diastolic function (deceleration time, isovolumetric contraction and e‟ velocity) were noted at 
six months after RDT in an uncontrolled study of 66 patients.[210]The changes in left 
ventricular mass were found to occur independently of blood pressure lowering. The same 
group of investigators also showed that RDT reduced left atrial size.[211] Others have 
demonstrated similar findings[206, 212-215], though this is not universal.[216] 
 
Diffuse myocardial fibrosis measured by T1 on cardiac MRI has also been shown to be 
reduced by RDT in small studies.[212, 213]  
 
2.6.4 Electrical remodelling 
There has been no effect upon heart rate with renal denervation from two randomised 
controlled trials.[195, 199] Six months after RDT, an improvement in global and regional 
atrial conduction was found on invasive electrophysiological testing.[212] Along with the 
cardiac remodelling, this might explain a reduction in AF recurrence seen in a small 
randomised controlled trial of RDT in patients with resistant hypertension undergoing AF 
ablation.[112] 
 
2.6.5 Vascular remodelling 
In a study that compared 40 patients who underwent RDT to 10 controls, the intervention was 
shown to reduce blood pressure, MSNA and augmentation index (a surrogate marker of 
peripheral arterial stiffness).[217] This remodelling was noted at three months post-
procedure.  
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Brandt and colleagues found similar reductions in markers of aortic stiffness but they 
assessed medium sized vessels using applanation tonometry at the radial, carotid and femoral 
arteries.[218] From these measurements augmentation index and pulse wave velocity were 
derived. Improvements in both parameters were seen in the active arm compared to control at 
three and six months. These findings have been reproduced by others groups.[219, 220] 
 
Endothelial function measured at the finger tips using reactive hyperaemia and laboratory 
markers of inflammation were not improved post RDT in 69 patients.[221] 
 
2.6.6 Renal remodelling 
RDT has been shown to increase sodium excretion independent of renal function and blood 
pressure medications.[222] Improvements in albuminuria following denervation have been 
noted by some [223-225] but not by others.[226, 227] The underlying mechanism of this 
improvement is not clear but is likely to be driven by improvements in blood pressure control 
and renal microvascular function. Indeed, RDT has not been consistently shown to either 
improve or worsen renal function measured by estimated glomerular filtration rate (eGFR) 
[156, 195, 199, 228] or imaging parameters for renal blood flow.[220, 226, 227, 229] 
 
2.7 Renal Denervation Therapy: Potential in Heart Failure 
The rationale for lowering SNS activation in heart failure including HFpEF has been 
summarised in a previous section; in essence, renal denervation may be an effective way to 
modulate SNS activity. The value of attenuating the renal sympathetic nerves in animal 
models of HFrEF has been established.[230-236] However, there are no animal models of 
HFpEF suitable for testing RDT and it is generally accepted that this limitation should not 
prevent human testing of promising therapies.[237] In the resistant hypertension population 
RDT has been shown to improve many of the abnormalities that are present in the HFpEF 
population lending support to investigate this further.  
 
The first publication of the use of RDT in human heart failure was the REACH-Pilot 
study.[238] The main purpose of this study was to assess the safety of RDT in patients with 
symptomatic heart failure (NYHA class III-IV) who are a sicker population than those with 
resistant hypertension.[35] They did not have an EF cut-off for inclusion; the mean EF of the 
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recruited patients was 43% ± 15(SD). After RDT, patients remained in hospital for five days 
for close observation, thereafter they were followed-up, weekly for a month and then monthly 
till six months were completed. In the seven recruited patients, there were no clinically 
significant blood pressure/heart rate changes or deterioration in renal function during the 
follow-up period. There was a small increase in six minute walk test distance (27.1±9.7m, 
p=0.03) and all patients subjectively felt better.   
 
There is one further report of RDT in human heart failure.[239] It is unclear whether it was a 
case-controlled study or a randomised trial. To be eligible, patients had to have NYHA III-IV 
symptoms and an EF<40% Ten patients received RDT with an unspecified radiofrequency 
ablation catheter and ten were in the control arm. 24 hours after the ablation, plasma 
biomarkers for renin, aldosterone, angiotensin II, dopamine, adrenaline, BNP and 
noradrenaline were reduced compared to the control arm. At six months follow-up there was 
an improvement in ejection fraction, left ventricular size, BNP and even major adverse 
cardiovascular events in the active arm compared to the control arm. These overwhelmingly 
encouraging results must be tempered against the limitations of this trial: small size, likely 
non randomised designed and non-blinded endpoint assessments. 
 
There are now multiple trials underway examining the role of RDT in patients with both 
HFrEF and HFpEF that over the coming years will expand our knowledge in this field (Table 
2.3). The Renal Denervation in Heart Failure with Preserved Ejection Fraction (RDT-PEF) 
trial is our contribution. 
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Trial ID 
Trial No Ejection 
Fraction Randomized Blinding Patients Endpoints 
 
 
    
S M CVE LV EX QoL NH 
Completed 
REACH Pilot NCT01584700 mean 43% No Open 7 1 
   
2 2 2 
Olomouc I 
Pilot NCT01870310 mean 25% Yes Open 51 2 
  
2 2 2 1 
Dai et al, 2015 Not registered mean 38% Unknown Open 20 1 2 2 2   2 
Recruiting 
HFrEF 
Symplicity HF NCT01392196 <40% No Open 40 1   2   2 
Swan HF NCT01402726 <40%, >45% Yes Open 200 1 1 1     
Bursa YIEAH NCT01538992 <35% Yes Open 20 1   2 2 2 2 
REACH NCT01639378 <40% Yes Single 100 2 2 2  2 1 2 
RSD4CHF NCT01790906 <35% Yes Open 200 2 1 1 2 2 2 2 
RE-ADAPT-
HF 
NCT02085668 
  <40% Yes Open 100 1   2 2 2 2 
RDN-Chagas NCT02099903 <40% (Chagas) Yes Open 30 1 1 1 2 2 2 2 
RDT-CRT 
NCT02329145 
  <35% Yes Open 20   1  1 1  
HFpEF 
DIASTOLE NCT01583881 >40% Yes Open 60 2   1    
RDT-PEF NCT01840059 >50% Yes Open 25 2 
  
1 1 1 1 
RESPECT-HF NCT02041130 >50% Yes Open 144 2 2 2 1 2 2 2 
IncorRDN-
ICFEN NCT02115230 >50% Yes Open 40 1 
  
1 2 2 2 
Table 2.3: Summary of key trials and their endpoints using renal denervation therapy in heart failure (data from clinicaltrials.gov) S- 
safety, M- mortality, CVE- Cardiovascular events, LV- dimension, function, mass, volumes, EX- six minute walk test, cardiopulmonary 
exercise testing, QoL- quality of life, NH- neurohormones. 1= (co)primary endpoint, 2= (co)secondary endpoint. Adapted from [169]. 
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2.8 Main Hypotheses 
1. Renal denervation in patients with heart failure and preserved ejection fraction will 
improve their symptoms and exercise performance. 
 
2. Renal denervation in patients with heart failure and preserved ejection fraction will lead 
to functional and structural cardiac remodelling. 
 
3. Renal denervation in patients with heart failure and preserved ejection fraction will 
reduce sympathetic over-activity. 
 
4. Renal denervation in patients with heart failure and preserved ejection fraction will 
induce micro and macro vascular remodelling. 
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3 General Methods 
 
3.1 Clinical trial design 
A prospective, randomised, open-allocation, controlled trial was designed to test the main 
hypotheses: the Renal DenervaTion in heart failure with Preserved Ejection Fraction (RDT-
PEF) trial.  
 
Patients were randomised, 2:1 (RDT:control). This unequal randomisation ratio was chosen 
to provide more data on the tolerability and potential risks of renal denervation in a 
population not previously offered this treatment but without significantly lowering study 
power.[240] 
 
At the time of designing this trial, the majority of experience with RDT was in patients with 
resistant hypertension. The key publication, SYMPLICITY HTN-2 had shown benefit of 
RDT over optimal medical therapy in a randomised, controlled and open label trial.[195] Our 
department at the Royal Brompton Hospital had performed seven RDT procedures for 
resistant hypertension by the time of starting the RDT-PEF trial using the Symplicity™ Flex 
catheter. The only published data of RDT in heart failure patients was from a pilot study of 
seven patients from another centre.[238] Due to the limited experience of this technique in 
the heart failure population, safety was an overarching consideration and hence, we opted for 
an open design. This does expose the trial to bias and to minimise this we pre-specified 
primary efficacy end-points to be analysed by blinded assessors (PROBE design).[241] 
 
The control group had no further interventions and were followed up with the same frequency 
and investigations as the active group. Other than for pressing clinical need, once patients 
were recruited into the study and optimal medical therapy established, further medication 
changes would not be advised. 
 
3.2 Patient selection 
The trial inclusion criteria are derived from the most recent European Society of Cardiology 
(ESC) heart failure guidelines.[7] Enriching criteria were added to sub-select patients on the 
more advanced end of the heart failure spectrum.  
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3.2.1 Inclusion Criteria 
 Age: 18-85 years 
 Able to give informed consent 
 Symptoms and/or signs of heart failure 
 NYHA class II-III 
 EF ≥50% 
 Non dilated left ventricle on transthoracic echocardiogram (LVEDD<60mm, 
LVESD<45mm) [7] 
 Either, 
o Dilated left atrium on transthoracic echocardiogram [242] 
 diameter in parasternal long axis >38mm (women)/>40mm (men) or  
 left atrial area> 20cm2 
or  
o Left ventricular hypertrophy on transthoracic echocardiogram [242] 
 Left ventricular wall thickness ≥12mm 
 Either,  
o E/e‟ (lateral)>10, E/e‟ (septal)>15 [243] 
or  
o Brain natriuretic peptide (BNP) ≥35 ng/L [7] 
 One presentation to hospital with heart failure (peripheral oedema or pulmonary 
oedema requiring intravenous diuretics) in the last 24 months 
 
3.2.2 Exclusion Criteria 
 Any other form of cardiomyopathy (e.g. constrictive, hypertrophic, restrictive, 
dilated) diagnosed 
 Previously documented LVEF<40% (i.e. recovered HFrEF) 
 Significant valvular disease (at least moderate aortic regurgitation/stenosis or mitral 
stenosis; or severe mitral regurgitation) 
 History of myocardial infarction, unstable angina or cerebrovascular accident in the 
last 6 months 
 Symptomatic orthostatic hypotension 
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 Unfavourable renal anatomy for RDT: severe renal artery stenosis, small artery (< 
4mm in diameter) 
 Type 1 diabetes 
 Estimated glomerular filtration rate (eGFR) <45ml/min/1.73m
2
 (based on 
Modification of Diet in Renal Disease criteria) 
 On treatment with clonidine, moxonidine, fludrocortisone 
 Contraindication to magnetic resonance imaging (MRI) 
 Pregnancy 
 
These were chosen to: 
1. Be consistent with the criteria used by recent HFpEF trials.[140, 153, 154]  
2. Maintain safety by not recruiting patients who might be recovering from recent 
cardiovascular events or those in whom renal denervation may not be safe. 
3. Include only patients with eligible renal artery anatomy. This were assessed by MRI 
(along with other cardiac endpoints) and hence patients with contraindications to MRI 
it were not be recruited. 
4. Match the exclusion criteria of SYMPLICITY HTN-2 [195] to satisfy the ethical 
review board: notably the eGFR cut-off, the exclusion of patients with type 1 diabetes 
and those on treatment with clonidine, moxonidine, fludrocortisone.  
 
3.3 Endpoints 
There is no single endpoint that captures the totality of the patient‟s experience with 
HFpEF.[244-247] The Cardiovascular Cell Therapy Research Network (CCTRN) has 
recommended that the measure of success of phase II clinical study should not hinge upon 
achievement of statistical significance for a small number of primary end-points (this being 
how phase III studies are designed) but rather investigate the effect of the treatment across a 
selection of endpoints addressing different categories of effects or domains without being 
overly concerned about suppressing the likelihood of false-positive findings.[247] The 
purpose of phase II studies is to show safety and uncover mechanistic pathways that may 
better guide design of phase III studies.[247] 
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The endpoints of this phase II study have been chosen to reflect the multiple pathways that 
are abnormally activated in HFpEF.  
 
3.3.1 Primary Endpoints 
The primary endpoints of the RDT-PEF trial assessed the domains of quality of life, 
functional capacity, biomarkers, cardiac physiology and structural remodelling: [247] 
 
 Minnesota Living with Heart Failure questionnaire (MLWHFQ) 
 Peak oxygen uptake (VO2) determined by cardio-pulmonary exercise testing 
 Brain natriuretic peptide (BNP) 
 Average E/e‟ from tissue Doppler of mitral valve annulus (septal and lateral) 
 Left ventricular mass index (LVMI) from CMR 
 Left atrial volume index (LAVI) from CMR 
  
3.3.2 Secondary Endpoints 
Investigating the role of RDT on: 
 Autonomic remodelling 
- Change in heart rate using 24hr ECG monitoring 
- Change in heart:mediastinum ratio (HMR) and wash-out (WO) rate on cardiac 
metaiodobenzylguanidine (mIBG) radiotracer imaging 
- Change in 24hr urine and plasma catecholamines 
- Acute changes in trans-renal and trans-cardiac catecholamine gradient 
 
 Vascular remodelling 
- Change in 24hr ambulatory blood pressure (BP) 
- Change in aorta strain and distensibility on aorta MRI 
- Change in microvascular endothelial function by reactive hyperaemic index 
- Change in renal blood flow and pulsatility 
 
3.3.3 Safety Endpoints 
To determine if RDT in patients who have HFpEF is unsafe as assessed by: 
 Deterioration in renal function (defined as eGFR decline >30% from baseline) 
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 Symptomatic hypotension that does not respond to medication alteration 
 Death, myocardial infarction, cerebro-vascular accident within hospital due to the 
procedure 
 Procedural safety outcomes 
- Femoral vascular injury needing surgery 
- Renal artery injury needing intervention 
- Hospital readmissions for procedure related complication 
 
3.4 Statistical Plan 
3.4.1 Sample Size 
Our primary endpoints have been described above. Trial success was defined a priori as a 
significant improvement of at least 3 of the 6 endpoints in the RDT group compared with the 
control group with a P value of <0.2. The unconventional higher threshold for the P value has 
been used in other trials and is justified because the statistical design imposes the additional 
constraint that no significant deterioration occurs in the RDT-treated patients for any of the 
end points.[247, 248] 
 
Clinically relevant changes in the outcomes and their standard deviations were taken from 
other studies as: ∆MLWHFQ (10, 13);[249] ∆VO2 peak (1.5, 2.5 ml/kg/min);[249] ∆BNP 
(50, 130 ng/l);[140] ∆E/e‟ (2, 3);[140] ∆LWMI (5, 11 g/m2)[211]; ∆LAVI (4, 4 ml/m2).[249]  
 
Using simulation, a sample size of 12 v 24 (control vs RDT) will have 85% power to detect a 
significant (unpaired, two-tailed t-test, p<0.2) improvement of 3 or more outcomes with no 
significant deterioration in any.[250] The simulated type 1 error rate is 0.037 in each 
direction; this is consistent with traditional trial statistics. This sample size calculation was 
formally performed by a statistician (BN, Senior Statistician, Wolfson Institute of 
Preventative Medicine, Queen Mary University of London) using R[251] and takes into 
account unequal randomisation and an estimated correlation between the outcomes of 0.2. 
 
To account for drop out and to increase the power to detect clinically relevant adverse events 
due to RSD in HFpEF patients we initially planned to recruit 50 patients. 
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3.4.2 Statistical analysis 
Continuous variables will be presented as mean (standard deviation) and compared using the 
t-test and analysis of variance. Non-normally distributed data will be presented as median 
(interquartile-range) and compared using the Mann-Whitney U test. Categorical data will be 
presented as counts and percentages and compared using the Fisher‟s Exact test. Changes 
were assessed on an intention-to-treat basis, by statistical tests of independent samples 
comparing absolute changes from baseline between the study groups. A general linear model 
was used to compare changes in the six primary endpoints between the two groups using 
baseline values as covariates and are presented as analysis of co-variance (ANCOVA) P 
values. SPSS (IBM v20) was used to perform the statistical analyses.  
 
3.5 Ethical Approval and Trial Registration 
This study was approved by the South East National Research Ethic Service (NRES) on 11 
February 2013 (12/LO/1941). Royal Brompton and Harefield NHS Trust gave R&D approval 
for the trial upon 17 April 2013. A substantial protocol amendment was approved by NRES 
on 11 October 2013. This amendment removed the requirement for heart failure 
hospitalisation in the previous 24 months and reduced the EF threshold to >40%. The 
rationale for this alteration was to improve recruitment and is discussed further in Chapter 4. 
 
The following ten heart failure units agreed to act as Patient Identification Centres (PIC) for 
this study and approval was granted from the research and development department of each: 
Ashford and St Peter‟s Hospitals NHS foundation trust (April 2013), Chelsea and 
Westminster Hospital NHS foundation trust (April 2013), Epsom and St Helier University 
Hospital NHS trust (April 2013), St George‟s Healthcare NHS trust (April 2013), Imperial 
College Healthcare NHS trust (May 2013), West Middlesex University Hospital NHS trust 
(June 2013), Royal Surrey County Hospital NHS foundation trust (July 2013), Frimley Park 
Hospital NHS foundation trust (August 2013), North West London Hospitals NHS trust 
(August 2013), Guy‟s and St Thomas‟ NHS foundation trust (April 2014). 
 
The RDT-PEF trial and its pre-specified endpoints were recorded prior to commencement on 
ClincalTrials.gov with identifier NCT01840059. 
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3.6 Recruitment 
This is described further in Chapter 5. Those patients who met the eligibility criteria upon 
initial screening were contacted with a patient information sheet and offered a meeting to 
discuss the trial further. If they agreed to take part in the trial a consent form was signed with 
the research team at the Royal Brompton Hospital site and initial baseline investigations 
started. 
 
3.7 Randomisation Protocol 
Randomisation was performed by the Biomedical Research Unit Manager via email. Patients 
were randomised 2:1 using the programme „ralloc‟ in Stata (StataCorp, College Station, TX, 
USA). The research team were blinded to block-size. 
 
3.8 Baseline and Follow-up Investigations 
All patients underwent a series of clinical assessments and investigations at baseline, three 
months post randomisation and 12 months as summarised in Table 3.1. All tests were 
performed at approximately the same time of day to minimise intra-day variability. 
 
All patients were allocated a sequential study code number to permit pseudo-anonymisation 
of the electronic case report form (an Excel spreadsheet). 
 
3.8.1 Clinical assessment 
This included recording symptoms, past medical history (diabetes, chronic obstructive 
pulmonary disease, hypertension, coronary artery disease, atrial fibrillation), medication 
history and physical examination. Height (nearest cm) and weight (nearest 100g) were 
measured using a manual telescopic height measure and an electronic scale (Marsden 
Weighing Group, UK). 
 
Body mass index (BMI, Kg/m
2
) was calculated as: weight (Kg)/ height
2
 (m). Body surface 
area (BSA, m
2
) was calculated using the Mosteller method as: (height (cm) x weight 
(kg)/3600)
1/2
. 
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Study Assessments Baseline Randomisation 3 months 
12 
months 
Clinical assessment  X 
 
 
Only patients 
randomised to 
active treatment 
will undergo an 
invasive 
procedure 
X X 
Questionnaire X X X 
Blood tests X X X 
Urine tests X X X 
24hr ECG Holter X X X 
24hr ambulatory BP X X X 
Echocardiogram X X X 
MRI- cardiac, aorta X X X 
MRI- renal X  X 
Cardiac mIBG scan X  X 
Cardio-pulmonary 
exercise test 
X X X 
Endothelial function 
test 
X X X 
Renal artery ablation  X   
Right heart 
catheterisation 
 X   
Table 3.1: Schedule of investigations for patients recruited into the RDT-PEF study 
 
3.8.2 Minnesota Living with Heart Failure Questionnaire 
The Minnesota Living with Heart Failure Questionnaire (MLWHHQ) is self-administered 
and has been shown to be reliable and valid in patients with heart failure.[252] It explores 
multiple dimensions of quality of life (physical, social and psychological) over the previous 
month. Higher scores suggest increased symptoms and reduced quality of life.[252] The 
questionnaire was administered to each patient at the beginning of each visit before any 
further clinical interactions.  
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3.8.3 Blood tests 
Blood was taken in all patients at the same time on each assessment day. Samples were taken 
for full blood count, urea and electrolytes, BNP, noradrenaline, adrenaline, renin and 
aldosterone. The samples were hand-delivered to the specimen laboratory for immediate 
processing. Plasma catecholamines, renin and aldosterone were batch processed and hence 
after centrifugation, plasma was frozen at -70°C. Plasma catecholamines were measured 
using high performance liquid chromatography (HPLC). Renin and aldosterone were 
measured using mass spectroscopy. BNP was measured by immunoassay on the Beckman 
Access 2 Immunoassay analyser (Beckman Coulter, UK). 
 
3.8.4 Urine test 
A random urine sample was taken for albumin:creatinine ratio (ACR).  
 
A 24 hour urine collection was performed using hydrochloric acid as preservative for urinary 
catecholamines. Patients were given standard written instructions.[253] Medications were not 
discontinued. Patients were asked not to consume coffee, tea, bananas, chocolate, cocoa, 
citrus fruit, vanilla or coca-cola for 24 hours prior to and during the collection. The sample 
was analysed using HPLC. 
 
3.8.5 24 hour (hr) ECG Holter 
A SEER 12 (General Electric- GE) digital Holter recorder was used to record a 24hr ECG 
with a 1024 Hz sample rate. The data was then uploaded on to a MARS ambulatory ECG 
system for analysis. The data were analysed semi-automatically and the following results 
were extracted: mean heart rate, minimum heart rate, maximum heart rate and ventricular 
ectopic count.  
 
ECG trace quality was optimised by skin preparation (shaving hair as necessary, using 
alcohol to clean the skin and gentle abrasion) and using appropriate electrodes. 
 
3.8.6 24hr Ambulatory Blood Pressure Monitoring 
A Spacelabs 90207 ambulatory blood pressure monitor was attached using an appropriately 
sized cuff to the non-dominant arm of the patient. It was attached for a period of 24 hr and 
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was analysed using automated and proprietary software. 24hr, day time (0800-2200) and 
night time (2200-0800) averages of blood pressure were obtained. The number of successful 
blood pressure recordings was also noted. 
 
3.8.7 Transthoracic Echocardiogram 
Echocardiography was performed with the subjects in the left lateral decubitus position on a 
fit-for-purpose table. A Philips iE33 machine with a S5-1 transducer was used for all studies.  
All scans fulfilled the requirements of the British Society of Echocardiography for the 
minimum dataset to be acquired for a resting echocardiogram. Patients in atrial fibrillation 
had a minimum of 3 loops or 3 Doppler envelopes recorded and the average of these was 
quoted in the quantitative report. Left ventricle (LV) dimensions were acquired in the 
parasternal long axis views. LV ejection fraction (EF) was calculated from biplane apical 
echocardiographic views using Simpson‟s method. Left atrial volume was estimated using the 
area-length method from the apical 2 and 4 chamber view. LV diastolic function was 
assessed using pulse-wave Doppler with the sample volume placed at the mitral valve tip 
(Figure 3.1). Tissue Doppler imaging with pulse wave was used to obtain septal and lateral 
mitral annular velocities (e
‟
) (Figure 3.2). M-mode was used to obtain tricuspid annular 
systole excursion (TAPSE). 
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Figure 3.1: Pulse wave velocity at the mitral valve leaflets to derive peak E velocity 
 
 
Figure 3.2: Tissue Doppler imaging of the medial mitral annulus with e’ and s’ 
annotated. 
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3.8.8 Cardiac and Aortic MRI (CMR) 
CMR was used to characterise left and right ventricular volumes and ejection fraction, left 
atrial volume, myocardial mass and qualitative myocardial scar (fibrosis) with late 
gadolinium enhancement (LGE), using standard methods.[254] 
 
3.8.8.1 Cardiac Chamber Volumes and Mass 
Images were acquired using a Siemens Avanto (1.5 Tesla) scanner as previously 
described.[254] ECG gating was performed throughout. In patients with atrial fibrillation 
prospective gating was used and in all other cases retrospective gating was preferred. Similar 
settings were replicated for follow up scans for each patient. After initial localiser and pilot 
scans were performed, long axis cines through the vertical long axis (two chamber), 
horizontal long axis (four chamber), left ventricular outflow and right ventricular outflow 
tract were obtained. Steady-state free precession sequences were used for the assessment of 
left (LV) and right (RV) ventricular volumes, left atrial volumes and LV mass. The slice 
thicknesses were 7mm with a 3mm interval. Typical parameters were as follows: voxel size 
2.1 x 2.1 x 7mm, 25 phases were acquired, TR 39ms, TE 1.1ms and flip angle 71°. 
Biventricular volumes, mass and function were calculated by a single blinded observer (GS) 
using a semi-automated software (CMRtools, CVIS, UK) as previously described.[255] 
Initially, the LV endocardial and epicardial borders were delineated in all cardiac phases. The 
systolic descent of the mitral valve was subsequently calculated from tracking of the valve 
motion in the long axis cines and used to correct for loss of systolic LV volume due to AV 
ring descent. Finally, blood pool thresholding was used to delineate the papillary muscles 
which were carefully excluded from the blood pool and considered part of the left ventricular 
mass (Figure 3.3). Atrial volumes were also calculated by a single blinded observer (VV) 
using a previously validated method.[256] In short, the LA maximum volume was measured 
using CMR tools. The atrial endocardial borders were delineated in all cardiac phases. The 
systolic descent of the mitral valve was calculated by the tracking of the valve motion in the 
long axis cines and used to correct for any increase in the atrial volume secondary to the AV 
ring descent. All atrial parameters were measured in the ventricular end-systolic phase of the 
corresponding cine sequences to enable measurement of maximum LA volume.  
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Figure 3.3: Left ventricular stack to assess LV volumes and mass by CMR. Reproduced 
from [257]. 
 
3.8.8.2 Aorta Distensibility 
A small field of view (read [left-right] 220ms, phase [anterior-posterior] 75%) axial dataset of 
the aorta at the level of the bifurcation of the main pulmonary artery was acquired using a 
balanced steady-state free precession cine sequence (Siemens “True FISP”). Parameters were 
as follows: voxel size 1.1 x 1.1 x 7mm, TR 45.3ms, TE 1.28ms, flip angle 65◦, reconstructed 
as 25 interpolated cardiac cine frames. The maximum and minimal cross sectional areas of 
the ascending and descending aorta were calculated using Art-FUN, an automated edge-
detection software for assessment of arterial function.[258] Aortic strain was defined as: 
(max cross-sectional aorta area- min cross-sectional aorta area)/ min cross-section aortic area 
(Figure 3.4).[259] Aortic distensibility (10
-3
.mmHg
-1
) was defined as: aortic strain/ brachial 
artery pulse pressure.[259] 
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Figure 3.4: Determination of the aortic cross-sectional area during a cardiac cycle. (A): 
automatic contouring of the ascending aorta. (B): ascending aorta cross-sectional area versus 
time curve; Ss and Sd correspond to the ascending aorta systolic and diastolic areas, 
respectively. Reproduced from [259] 
 
3.8.8.3 Pulse Wave Velocity 
Velocity encoded with phase contrast sequences were acquired of an axial dataset of the aorta 
at the level of the bifurcation of the main pulmonary artery perpendicularly transecting both 
the ascending and descending aorta. A non-breath-hold sequence was used and 128 phases 
were captured. The parameters were as follows: voxel size 2.8 x 2.1 x 10mm, TR 8.45ms, TE 
2.10ms, flip angle 18◦. The transit time of the propagation of the velocity waveform was 
calculated between the ascending and descending aorta using the Art-FUN software with the 
least squares minimisation approach using all data points on the systolic upslope of the aorta 
flows after peak flow normalisation.[258, 259] The process is automated and requires the 
user only to point the centre of the aorta and any point on the aorta wall on one cine image.  
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Figure 3.5: Transit time method using Art-FUN for calculating pulse wave velocity. A: 
The double oblique view of the thoracic aorta to derive aorta path length (d) at the level 
of the pulmonary artery (PA). B: Magnitude image of the transaxial slice at the level of 
the PA, piloted on image A. C: Velocity flow map of B. D: Velocity curves of the 
ascending and descending aorta from a patient after normalisation. E: Least squares 
estimation of the transit time (marked by the green vertical line).  
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The aortic path length was calculated from the double-oblique view of the thoracic aorta 
using 4-8 markers on the centreline of the aorta, with the first and final maker positioned at 
the centre of ascending and descending aorta plane used for the velocity acquisition. Pulse 
wave velocity (m/s) was derived as aortic path length divided by the transit time (Figure 3.5). 
 
3.8.8.4 Late Gadolinium Imaging 
Late gadolinium enhancement (LGE) images were acquired 10 minutes following the 
administration of gadobutrol (Gadovist®) at a dose of 0.1ml/Kg. LGE was reported using the 
17 segment myocardial model and as midwall, subendocardial (0-50% of the myocardium) or 
transmural (>50% of the myocardium). An inversion-recovery gradient echo sequence was 
used to identify LGE, in identical long-axis and short-axis planes. Inversion times were 
optimized to null normal myocardium. The images were repeated in two separate phase-
encoding directions. LGE was deemed present if there was a bright signal in the myocardium 
(distinct from the blood pool) that persisted in both phase-encoding directions and in two 
orthogonal views. 
 
3.8.9 Renal MRI 
Images were acquired using the Siemens Skyra (3.0 Tesla) scanner. After initial scouts and 
localisers, a coronal T1 fast low angle shot (FLASH) -gradient sequence (voxel size 1mm x 
1mmx 5mm; slice thickness 5mm; TR 163ms; TE 3.69ms; flip angle 70◦) and a T2 turbo 
inversion recovery magnitude (TIRM) sequence (voxel size 1.2mm x 1.2mmx 5mm; slice 
thickness 5mm; TR 3300ms; TE 89ms; flip angle 160◦) was performed for assessment of 
renal anatomy (Figure 3.6). Renal arteries were imaged using a 3D FLASH sequence (voxel 
size 1mm x 1mmx 1mm; slice thickness 1mm; TR 3.84ms; TE 1.28ms; flip angle 25◦) in the 
coronal plane using an automated dual headed injector to deliver gadobutrol at a dose of 
0.1ml/Kg followed by a saline flush (Figure 3.7).  
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Figure 3.6: Coronal T1 FLASH sequence for imaging the kidneys 
 
Renal artery blood flow was assessed by applying a spiral flow sequence (voxel size 0.5mm x 
0.5mm x 8mm; FOV read 250mm, FOV phase 4.7%; TR 23.46ms; TE 5ms; flip angle 15◦) 
on a through-plane image of the proximal renal artery reconstructed from the maximum 
intensity projection (MIP) of the renal magnetic resonance angiography (MRA). Velocity 
encoding (VENC) was set at 150 cm/s but altered if there was evidence of aliasing. In 
patients with sinus rhythm retrospective gating was used and trigger gating was used in 
patients with atrial fibrillation. Scan parameters were replicated for follow-up scans on an 
individual patient basis. To acquire individual renal artery blood flow graphs, regions of 
interests were drawn on the magnitude images of an axial cut through the renal artery and 
used to derive a time velocity curve from the spiral flow images (Figure 3.8). 
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Figure 3.7: Magnetic resonance angiography of the renal arteries 
 
 
Figure 3.8: Time-velocity curve of the right renal artery in one healthy individual using 
the spiral sequence. Red and blue lines represent separate scans on the same volunteer. 
Reproduced from [260] under Creative Commons Attribution licence. 
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Figure 3.9: Bland-Altman plots showing reproducibility of measurements of renal 
artery cross-sectional area, blood flow, mean renal artery velocity, resistive index (RI) 
and pulsatility index (PI) with: a) between observers and b) between studies. Reproduced 
from [260] under Creative Commons Attribution licence. 
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3.8.10 Cardiac mIBG 
Standardised techniques were used. Patients were asked to refrain from caffeine, vanilla, 
chocolate and blue cheese for 24 hr prior. Certain classes of medications were withheld prior 
to the test and these included calcium channel blockers, tricyclic anti-depressants and nasal 
decongestants. On the day of the test patients received 400mg of potassium perchlorate 
(thyroid protection) at least 30 minutes before injection of the radiotracer, 
123
I- 
metaiodobenzylguanidine (mIBG). The radiotracer was acquired from Mallinckrodt 
Radiopharmacy Services. A dose of 200 MBq (if BMI≤35) and 400 MBq (if BMI>35) was 
injected. The same dose was used for the follow-up scan as was in the baseline for each 
patient. 
 
A GE Infinia Hawkeye scanner was used to acquire anterior and posterior planar images of 
the mediastinum and abdomen at 15 minutes after injection and at 4 hours. Imaging was 
performed with low-energy/high resolution collimators, and the camera peaked at 159 keV 
with a +/- 10% energy window. The images were acquired and stored in a 128×128 matrix. 
Single-photon emission computed tomography (SPECT) using either the GE Infinia or 
Spectrum Dynamics (D-Spect) solid state scanner was performed after the planar images 
taken at 4 hours. 
 
A heart/mediastinum ratio was calculated from using the mean pixel counts from a hand 
drawing of a region of interest (ROI) over the cardiac shadow including the cavity and the 
upper mediastinum avoiding the thyroid gland using the delayed anterior planar image. A 
myocardial washout rate (WR) was calculated as:  
 
WR =  (He-Me)- [(Hl-Ml) x 1.21]  x 100 
                            (He-Me) 
, where H= mean pixel count from ROI of heart; M= mean pixel count from ROI of 
mediastinum; e= early; l= late (Figure 3.10); 1.21 is the calculated decay factor for the late 
images. 
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Patients with a higher washout rate (indicative of higher adrenergic drive) and lower late 
HMR (indicative of neuronal function including uptake and release of mIBG) have a worse 
prognosis in heart failure.[261]  
 
Agreement between cardiac mIBG measurements at our institute were assessed with a re-
analysis of a random selection of ten baseline scans using the Bland-Altman method. There 
was good agreement between cardiac mIBG measurements with a bias of 0.02 (95% 
confidence interval [CI]: -0.06, 0.10] for late HMR and a bias of -0.49% (95% CI: -3.20, 
2.22) for WO rate. 
 
 
Figure 3.10: Early (left) and late (right) planar images following mIBG injection. Region 
of interests (ROI) are drawn around the heart and a small ROI is shown in the mediastinum 
on late image. Counts from within the ROIs are then used to calculate the late 
heart:mediastinum and the washout rate. 
 
3.8.11 Cardiopulmonary exercise testing 
All tests were performed using a Medgraphics Ultima CPX (Medical Graphics Corporation, 
Minnesota, USA) metabolic cart. The machine was calibrated before each study. Spirometry 
was performed at baseline and forced vital capacity (FVC) and forced expiratory volume in 1 
second (FEV1) was recorded (best of three). Throughout the test, the patients had continuous 
beat to beat heart rate monitoring, an ECG was recorded every three minutes, blood pressure 
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was taken manually every three minutes and there was continuous respiratory gas analysis 
(data expressed as 15 second means).  
 
Exercise was performed on a treadmill to symptom-limited maximum using the modified 
Bruce protocol. For those patients in whom the modified Bruce protocol was not tolerated, 
after a 5 minute rest period, a slower-onset protocol was used. The details of protocol used 
were recorded and reproduced at each assessment. 
 
The results were analysed and reported by physiologists blinded to randomisation allocation. 
A respiratory exchange ratio (RER) ≥1.10 at peak exercise, which is calculated as VCO2/VO2 
(carbon dioxide output/ oxygen consumption), was used as a marker for maximal exercise. 
Peak VO2 was calculated as the highest O2 uptake average over the last 1 minute of exercise. 
VE/VCO2 (minute ventilation/carbon dioxide output) slope was calculated using linear 
regression of all data points from onset of exercise to the end. Ventilatory threshold was 
calculated using the V-slope technique, which was derived as the point where change in VO2 
moves away from a line of identity drawn though a plot of VO2 versus VCO2. Oxygen uptake 
efficiency slope (OUES) represents that gradient of the line derived from plotting log VE and 
VO2 during the exercise period. All measurements are fully automated apart from 
identification of the point of the first ventilatory threshold; this was performed by an observer 
blinded to allocation. 
 
3.8.12 Endothelial function 
This was assessed using the EndoPAT™ 2000 device (Itamar Medical, Israel). It records the 
arterial waveform at the fingertip (one probe on each arm). A rapid cuff inflator (E20, 
Hokanson, USA) was place on upper right arm of each patient and set to inflate to a pressure 
of 200mmHg or 50mmHg above they patient‟s systolic pressure (whichever is greater). The 
test was performed under standardized conditions, in a quiet, temperature-controlled room 
using arm supports. After the patient was attached to the hardware and had an opportunity to 
acclimatise to it, a six minute rest period is recorded, followed by five minutes when the cuff 
is inflated to occlude the right brachial artery, and finally five minutes of recover with the 
cuff deflated (hyperaemic period). The proprietary software calculates the reactive 
hyperaemia index (RHI) and augmentation index (AI) which is a measure of arterial stiffness 
based upon these readings. The RHI is calculated as the post-to-pre occlusion pulse amplitude 
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tonogram signal in the occluded arm relative to the control arm, corrected for baseline 
vascular tone of the occluded arm (Figure 3.11). The natural log of RHI in validation studies 
provided a better approximation to the normal distribution and hence is presented.[262] RHI 
values greater than 1.67 and LnRHI values greater than 0.51 are considered normal by the 
manufacturers.[262] 
 
 
Figure 3.11: Reactive hyperaemia at the fingertip as assessed by the EndoPAT™ device. 
The patient on the left has normal reactivity (Ln RHI >0.51)  after 5 minutes of brachial 
artery occlusion compared to the patients on the right. 
 
AI is calculated as the difference between the second and first systolic peak of a pressure 
waveform expressed as a percentage of the pulse pressure. It is calculated from readings in 
the six minute baseline period. As AI is heart rate related, EndoPAT™ also performs a 
correction and presents the result as AI at a heart rate of 75 beats-per-min (AI@75bpm) 
(Figure 3.12). Lower AI values, which can be negative, suggest better arterial elasticity. 
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Figure 3.12: Tracing from EndoPAT showing derivation of augmentation index which 
is derived as (P2-P1)/P1 x 100 
 
3.9 Renal denervation 
The technique has been previously described (Chapter 2).[195] The original Symplicity™ 
Flex unipolar non-irrigated catheter was used as this was the catheter with the most 
supporting evidence of efficacy and safety at the time of starting this study. Patients were 
mandated to stay in overnight after the procedure. 
 
During the procedure trans-organ blood samples were taken as were haemodynamic cardiac 
measurements. 
 
3.9.1 Trans-organ catecholamine gradient 
Just prior to and immediately after the renal denervation procedure blood samples were taken 
from the coronary sinus, renal veins and aorta for plasma catecholamines. The coronary sinus 
and renal veins was intubated with either an AL-1, AL-2 or right coronary guide catheter with 
side holes. 
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3.9.2 Intra-cardiac haemodynamic measurement 
Prior to performing denervation and receiving any intravenous medications, patients 
underwent a right heart catheterisation using a 7Fr balloon tipped catheter in a fasting state. 
Lidocaine local anaesthetic was used to achieve femoral vein access. No intravenous 
analgesia or sedatives were given. 5000 units of heparin were administered. The system was 
„zeroed‟ to atmospheric pressure at the level of the heart before any recordings. A 7Fr 
thermodilution balloon-tipped catheter was advanced to the right atrium, right ventricle, 
pulmonary artery and wedge position. Blood pressures traces were recorded in each position 
at end-expiration. A blood saturation >95% was used to confirm an adequate wedge position. 
Cardiac output (Litres/min) was calculated using themodilution (multiple measurements were 
taken until there was less than 10% variability in readings) and the indirect Fick method 
(using blood oxygen content from samples from the pulmonary artery and aorta) as an 
internal check.[263] A left ventricular end diastolic pressure (LVEDP) was obtained using a 6 
Fr pigtail catheter advanced via the femoral artery into the left ventricle. Trans-pulmonary 
gradient (TPG) was calculated as: mean pulmonary artery pressure (PAP) – mean pulmonary 
capillary wedge pressure (PCWP). Pulmonary artery resistance (dynes/sec/cm
5
) was 
calculated as: TPG/cardiac output  x 80.[263] All pressure traces were visually inspected to 
derive the pressure averages (mmHg). LVEDP was taken as the pressure after the „A‟ wave at 
the onset of isovolumetic contraction in time with the R-wave on ECG. 
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4 Recruitment into an HFpEF clinical trial: experience of 
screening hospitalised heart failure episodes 
 
4.1 Introduction 
The background and design of the RDT-PEF trial has been described in Chapter 1-3. As 
hospitalisation for heart failure was one of the inclusion criteria for the RDT-PEF trial, logs 
of patients with hospitalised heart failure (HHF) were used as a sampling frame for screening.  
In this chapter I will describe this experience. 
 
4.2 Methods 
In England, hospitals are routinely expected to report key parameters about each heart failure 
admission to the National Institute for Cardiovascular Outcomes Research (NICOR). I used 
these data to screen patients. Where a comprehensive list of admissions for NICOR was not 
available, hospital admissions with heart failure coded as the primary diagnosis were 
reviewed as well.  
 
Medical records of each consecutive HHF patient across ten hospitals in England were 
reviewed. Each hospital had an emergency department through which acutely decompensated 
heart failure patients could present for urgent assessment. Patients could be coded as heart 
failure for NICOR only after clinical review by a member of the heart failure team. A 
minimum 12 month period was retrospectively scrutinised at each hospital. 
 
A HHF episode was confirmed upon review if the patient required intravenous diuretics for 
either pulmonary oedema or peripheral oedema. The reports of all investigations conducted 
before and after the index hospitalisation were interrogated. Patients that were incorrectly 
coded as heart failure were excluded from further analysis. A series of filters, encompassing 
the inclusion and exclusion criteria of the RDT-PEF were systematically applied (Figure 4.1). 
Filter 1 selects patients with an EF≥50%, filter 2 reflects the key exclusion criteria and 
removes individuals who have significant valve disease, diagnosed cardiomyopathy, age >85 
years and reduced renal function, finally filter 3 requires evidence of appropriate structural 
remodelling and either an elevated natriuretic peptide or evidence of raised left ventricular 
filling pressures. 
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Continuous data are presented as means (standard deviation [SD]). Categorical data are 
presented as counts (percentages) and comparisons are performed with Fisher‟s exact test. 
 
 
Figure 4.1: Filters applied to facilitate screening of hospitalised heart failure patients. 
Figure adapted from [264] 
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4.3 Results 
A total of 7093 patient admissions were reviewed. After exclusion of repeated admissions 
(n=253) and patients in whom the admission was not a heart failure decompensation (n=359), 
there remained 6481 individual patients who had experienced at least one heart failure 
admission.  
 
The mean age of these 6481 patients was 77.1 years (SD 12.6). 3821 (59.0%) were male. The 
sequential effects of the three filters are shown in an accurately proportioned box chart 
(Figure 4.2); only 40 (0.6%) patients from the whole HHF cohort were suitable for the RDT-
PEF trial. 
 
 
Figure 4.2: Box chart demonstrating the effect of applying the three filters to patients 
hospitalised with heart failure as screening for the RDT-PEF trial. Figure adapted from 
[264] 
 
The majority of patients were excluded as their EF was <50% (78.1%). The underlying 
reasons for screen failure from filter 2 and 3 are summarised in Figure 4.3. Ninety-four per 
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cent of the patients excluded by filter 2 were due either to increased age, haemodynamically 
significant valve disease, an eGFR <45 or a combination of the three. Over a third of the 
patients failed screening on at least two of the filter 2 criteria. In the application of filter 3, 
eight patients were found to have neither structural remodelling consistent with diastolic 
dysfunction or evidence of raised filling pressures. 
 
The proportion of patients with HHF and an EF ≥ 50% varied between tertiary centres and 
district general hospitals (43.6% vs 14.1 %, p<0.001). After application of filter 2 and 3 the 
proportion of patients suitable for consideration in the RDT-PEF trial remained higher in the 
tertiary centres (1.8 % vs 1.5 %, p=0.004) 
 
 
Figure 4.3: Bar chart illustrating underlying reasons for screen failure due to filters 2 
and 3. Figure adapted from [264] 
 
4.4 Discussion 
The key findings of this screening process are: 1. In England 21.9% of hospitalised heart 
failure patients have an EF≥ 50%; and 2. Increasing stringency in defining HFpEF to capture 
a more homogenous population suitable for inclusion into the RDT-PEF trial reduces the 
proportion eligible to only 0.6% of the whole HHF population. 
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Large epidemiology studies, predominately from the US have suggested that HFpEF (their 
definition constituting usually of a heart failure admission and a documented EF≥ 40-55%) 
constitutes 40-50% of all heart failure (Table 1.2).[17, 20, 27, 31] Our findings show this 
proportion to be strikingly smaller. Three possible explanations for this discrepancy include: 
1. Patients with HFpEF may represent a smaller proportion of all HHF in England; 2. The 
exclusion criteria of the RDT-PEF study are too stringent and have excessive reduced the size 
of the cohort with the diagnosis; 3 There is an under-diagnosis of HFpEF. 
 
A recent review of the iPRESERVE, CHARM series and CORONA trials (in total two 
HFpEF and three HFrEF cohorts) characterised baseline features and outcomes of the 
recruited patients according to four geographical locations: Eastern Europe/Russia, Western 
Europe, North America and Latin America.[265] Interestingly, there were significant regional 
differences in key baseline features including age, body mass index, renal function and 
natriuretic peptide as well as the outcome of heart failure hospitalisation or mortality. These 
discrepancies were more pronounced in the HFpEF trials compared to HFrEF.[265] These 
data along with the screening experience for the RDT-PEF study suggest there are differences 
in how HFpEF is diagnosed globally and might be adjusted for in future trials by better 
defining the patients to be enrolled. 
 
By using stricter yet appropriate criteria to identify a homogenous group of patients to study 
(Filter 1-3) the study population does become significantly smaller and this would affect not 
only generalizability of any findings but would require co-ordination of  heart failure 
networks to make recruitment feasible.[266] Filter 2 was responsible for excluding over 90% 
of patients with an EF≥50%. The criteria that composed filter 2 are justified. Excluding 
patients with significant valve disease and other cardiomyopathies are important as these are 
phenotypes that have an evidence base for specific treatments. Patients with these phenotypes 
have been excluded from previous HFpEF trials.[133, 141, 150] Patients with chronic kidney 
disease are also commonly not recruited into HFpEF trials.[107, 130, 132, 133, 141, 150] The 
underlying reason for this is safety; many of the treatments tested to date in HFpEF also have 
the potential to worsen renal function and potentially outcomes. Indeed in a post-hoc analysis 
of iPRESERVE, those patients who had worsening renal function were significantly more 
likely to experience cardiovascular death or heart failure hospitalisation.[136] Our threshold 
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of excluding patients with an eGFR <45 ml/min/1.73m
2
 was based upon published evidence 
at the start of the RDT-PEF trial of safety in patients using this criteria. Though there was 
emerging evidence of safety and feasibility of performing RDT in patients with resistant 
hypertension with moderate to severe chronic kidney disease, the trial ethics committee 
insisted that using a lower eGFR threshold would be a safety concern.[227] Finally, in 
appreciation of the fact that HFpEF tends to affect older individuals we set the upper limit of 
recruitment to 85 years of age.[13] 
 
As discussed in Chapter 1, using an ejection fraction as a cut-off in the classification of 
HFpEF is flawed but currently remains in the guidelines due to the current absence of a better 
method.[48] In HFpEF trials the cut-off utilised has varied from 35-55%.[27, 141, 143] The 
lower the cut-off is, the greater the pool of patients potentially with HFpEF to screen from. In 
the Cardiovascular Health Study, the proportion of patients with HFpEF rose from 55% to 
80% when the EF cut-off was reduced from ≥55% to ≥ 45%.[27] The ESC Heart Failure 
guidelines classifies those patients with an EF in the 40-50% to be in the „grey zone‟ and 
though patients in this zone may have HFpEF other phenotypes of heart failure are just as 
likely if not more.[7] Another pitfall of using an EF cut-off from a single measurement is that 
it is not overly sensitive and the minimum detectable difference is 10% in EF (biplane 
Simpson‟s method on echocardiography), i.e. an individual with an apparent EF of 45% may 
actually have a value of 51% if re-measured the following week.[70] 
 
Interestingly, from my screening, the prevalence of HFpEF was higher in tertiary centres than 
district general hospitals. The reasons for this merit further study but may be explained by the 
greater resources available to tertiary centres to identify HFpEF (including easy access to 
natriuretic peptide testing and daily heart failure nurse presence on the acute medical wards). 
 
4.4.1 Limitations 
The findings of this screening experience must be tempered against the fact that it is 
retrospective making any conclusions hypothesis generating only. Echocardiography was 
available for all patients; however, this was not true for natriuretic peptide levels, which were 
infrequently tested outside of the tertiary centres. The impact of this on filter 3, is likely to be 
minimal as ultimately only 34 patients who reached that stage did not have an elevated BNP 
(or it was not tested) or evidence of raised left ventricular filling pressures. 
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4.4.2 Conclusion 
Recruiting to an HFpEF trial is difficult, from a cohort of 6481 patients with hospitalised 
heart failure, only 0.6% (40) were eventually suitable to be approached after applying a series 
of inclusion and exclusion criteria. With this knowledge, the RDT-PEF study team requested 
a major revision to the ethical review committee, for removing the requirement for 
hospitalisation in the previous 24 months from the inclusion criteria and reducing the EF cut-
off to >40%. These enabled screening in cardiac outpatients and increase the sampling frame. 
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5 RDT-PEF study participant flow and summary of baseline 
characteristics of randomised patients 
 
5.1 Introduction 
The rationale and aims of the RDT-PEF study have been described in Chapter 1&2.  
In this chapter, I will summarise the characteristics of the patient population that was 
recruited and randomised into the RDT-PEF trial 
 
5.2 Methods 
Patients recruited into this study were derived from screening hospitalised heart failure 
records (Chapter 4), the Royal Brompton Hospital cardiology out-patient clinics, a teaching 
hospital heart failure diagnostic clinic and referrals from other centres. Briefly if the patient 
was identified as potentially suitable for the trial (i.e. they satisfied the selection criteria- 
Chapter 3), a clinician involved in the patient‟s care would approach them regarding the 
RDT-PEF trial. If the patient expressed interest, they would be offered an opportunity to meet 
with the clinical research fellow and receive a Patient Information Sheet with a follow-up 
consultation to discuss any further questions. Those patients who consented to participate 
underwent baseline investigations, followed by randomisation.  
 
The baseline assessments performed on all patients recruited into the trial are described in 
Chapter 3. Right heart catheterisation (RHC) was performed only in those patients allocated 
RDT. Haemodynamic data was collected before performing any ablations and prior to 
administration of intravenous opioid, sedation or fluid. 
 
5.2.1 Statistics 
Normality was subjectively assessed using histograms and statistically with the Shapiro-Wilk 
test. Data are presented as counts (percent), mean (standard deviation) or median (inter-
quartile spread). Fisher‟s exact test, independent sample‟s t test and Mann-Whitney-U test are 
used to assess whether randomisation was balanced. A P<0.05 is considered statistically 
significant. 
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5.3 Results 
Figure 5.1 summarises the number of patients screened and those finally randomised at the 
Royal Brompton Hospital for the RDT-PEF trial in the form of a Consolidated Standards of 
Reporting Trials (CONSORT) flow diagram. 10 228 patients were screened and this 
eventually distilled to 25 patients consented and randomised. Chapter 4 provides greater 
detail regarding the exact causes of screen failure in the hospitalised heart failure cohort.  
Ultimately seventeen patients were randomised to the active arm and eight to the control. All 
patients randomised to RDT, received treatment within four weeks. One patient was unable to 
attend their three month assessment due to a skiing accident (which was deemed unrelated to 
the RDT procedure) but did complete the 12 month assessment. One patient who was 
allocated to control withdrew consent after completing their three month assessment due to 
deterioration in their mobility. A further three patients were unable to undergo 
cardiopulmonary exercise testing due to mobility problems at their 12 month assessment. 
 
The characteristics of the patients randomised to receive RDT or control were statistically 
balanced at baseline and are summarised in Table 5.1.   
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Figure 5.1: CONSORT flow diagram for the RDT-PEF study . No.- number; HHF- 
hospitalised heart failure; RBH: Royal Brompton Hospital; HF: heart failure 
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 Total (n=25) RDT (n=17) Control (n=8) P (RDT vs Control) 
Demographics 
Age 74.3 ± 6.1 74.1 ± 6.8 74.6 ± 4.8 0.852 
Male 15 (60%) 11 (64.7%) 4 (50.0%) 0.667 
Ethnicity 
  Caucasian 
  Black 
  Asian 
  Arabic 
 
18 (72%) 
1 (4%) 
5 (20%) 
1 (4%) 
 
10 (58.8%) 
1 (5.9%) 
5 (29.4%) 
1 (5.9%) 
 
8 (100%) 
0 (0%) 
0 (0%) 
0 (0%) 
0.272 
BMI (Kg/m
2
) 30.6 ± 5.5 30.5 ± 4.6 30.8 ± 7.4 0.911 
BSA (m
2
) 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.3 0.897 
Past Medical History 
Hypertension 18 (72%) 14 (82.4%) 4 (50.0%) 0.156 
Diabetes 10 (40%) 8 (47.1%) 2 (25.0%) 0.402 
CVA 1 (4%) 1 (5.9%) 0 (0.0%) 1.000 
CHD 6 (24%) 5 (29.4%) 1 (12.5%) 0.624 
AF 15 (60%) 10 (58.8%) 5 (62.5%) 1.000 
Cardiac Surgery 7 (28%) 4 (23.5%) 3 (37.5%) 0.640 
OSA 4 (16%) 3 (17.6%) 1 (12.5%) 1.000 
COPD 6 (24%) 4 (23.5%) 2 (25.0) 1.000 
Cancer 4 (16%) 4 (23.5%) 0 (0.0%) 0.269 
Clinical Assessments 
MLWHFQ 47 (25-54) 48 (27-56) 28 (25-50) 0.351 
A SBP (mmHg) 125 ± 13.9 128 ± 15.0 120 ± 9.7 0.190 
A DBP (mmHg) 71 ± 8.2 71 ± 9.4 71 ± 5.1 0.866 
A HR (b/m) 73 ± 12.2 73 ± 13.7 72 ± 9.0 0.781 
Medications 
ACEi/ARB 23 (92%) 16 (94.1%) 7 (87.5%) 1.000 
Alpha-blockers 4 (16%) 2 (11.8%) 2 (25.0%) 0.570 
Beta-blockers 18 (72%) 12 (70.6%) 6 (75.0%) 1.000 
CC-blockers 8 (32%) 7 (41.2%) 1 (12.5%) 0.205 
Loop diuretics 21 (84%) 16 (94.1%) 5 (62.5%) 0.081 
Spironolactone 6 (24%) 6 (35.3%) 0 (0.0%) 0.129 
Laboratory Tests 
Haemoglobin 
(g/dL) 
131 ± 16 129 ± 16.4 135 ± 15.5 0.455 
eGFR 
(ml/min/1.73m
2
) 
61 (49.5-67.5) 61 (50.5-68) 61 (48.5-67.3) 0.887 
BNP (ng/L) 184 (122-287) 210 (137-354) 149 (99-205) 0.124 
Noradrenaline 3.73 ± 1.18 3.91 ± 1.29 3.34 ± 0.85 0.270 
Urine NA 247 ± 87.9 248 ± 97.7 245 ± 68.4 0.920 
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Echocardiography 
Septal e’ (cm/s) 5.89 ± 2.20 6.22 ± 2.45 5.18 ± 1.43 0.283 
Lateral e’ (cm/s) 8.73 ± 3.04 8.50 ± 3.31 9.23 ± 2.52 0.590 
Average E/e’  13.8 ± 5.3 13.6 ± 5.9 14.4 ± 3.9 0.747 
TAPSE (mm) 17.8 ± 5.7 18.2 ± 5.7 16.7 ± 5.8 0.586 
Magnetic Resonance Imaging 
iLV Mass (g/m
2
) 63.4 ± 10.4 62.9 ± 11.4 64.6 ± 7.1 0.653 
LV EF (%) 66.3 ± 9.1 66.8 ± 8.9 65.3 ± 10.1 0.696 
LV EF < 50% 0 (0%) 0 (0%) 0 (0%) 1.000 
iRV Mass (g/m
2
) 32.9 ± 5.7 33.0 ± 6.4 32.5 ±4.0 0.844 
RV EF (%) 62.2 ± 7.3 62.4 ± 7.4 61.9 ± 7.7 0.869 
iLA Volume 
(ml/m
2
) 
62.3 ± 28.1 62.8 ± 29.2 61.3 ± 21.7 0.905 
LGE Pattern 
Nil 
Endocardial  
Midwall 
 
13 (52%) 
7 (28%) 
5 (20%) 
 
9 (52.9%) 
5 (29.4%) 
3 (17.6%) 
 
4 (50%) 
2 (25%) 
2 (25%) 
 
1.000 
Cardio-Pulmonary Exercise Testing  
VO2 Peak 
(ml/Kg/min) 
15.6 ± 3.6 14.7 ± 3.3 17.5 ± 3.8 0.073 
VO2 Peak (% 
predicted) 
78.0 ± 19.1 74.0 ± 20.0 86.4 ± 14.7 0.136 
AT/predicted 
VO2 peak (%) 
59.2 ± 15.3 55.4 ± 16.0 67.4 ± 10.7 0.068 
OUES 1450 ± 622 1347 ±549 1667 ± 746 0.239 
VE/VCO2 Slope 36.0 ± 7.7 35.5 ± 6.5 37.3 ± 10.2 0.600 
Cardiac mIBG 
HMR Early 1.58 (1.49- 
1.76) 
1.64 (1.52- 
1.80) 
1.55 (1.45- 
1.69) 
0.315 
HMR Late 1.50 ± 0.18 1.53 ± 0.20 1.44 ± 0.13 0.289 
Washout Rate 
(%) 
35.5 ± 15.4  36.7 ± 15.2 33.0 ± 16.6 0.591 
Vascular Stiffness 
Ascending 
Aorta strain (%) 
3.55 (2.57-
5.98) 
3.55 (2.18-
7.55) 
3.63 (2.62-
5.23) 
0.977 
Aorta 
distensibility 
(10
-3
.mmHg
-1
) 
0.69 (0.41-
0.91) 
0.66 (0.41-
1.19) 
0.75 (0.42-
0.87) 
0.798 
PWV (m/s) 9.61 (6.63-
11.99) 
9.61 (5.62-
11.74) 
9.03 (6.73-
19.66) 
0.466 
lnRHI 0.45 ± 0.26 0.39 ± 0.21 0.56 ± 0.34 0.133 
AI@75bpm (%)  4.16 ± 17.2 2.71 ± 19.5 7.25 ± 11.3 0.549 
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Table 5.1: Baseline characteristics of the RDT-PEF population . Study primary endpoints 
are highlighted in green. BMI- body mass index; BSA- body surface area; CVA- 
cerebrovascular accident; CHD- coronary heart disease; AF- atrial fibrillation; OSA- 
obstructive sleep apnoea; COPD- chronic obstructive pulmonary disease; MLWHFQ- 
Minnesota Living with Heart Failure Questionnaire; A- ambulatory; SBP- systolic blood 
pressure; DBP- diastolic blood pressure; HR- heart rate; ACEi- angiotensin converting 
enzyme inhibitor; ARB- angiotensin receptor blocker; CC- calcium channel; eGFR- 
estimated glomerular filtration rate; BNP- brain-type natriuretic peptide; NA- noradrenaline; 
LV- left ventricle; EF- ejection fraction; i- indexed for body surface area; RV- right ventricle; 
LA- left atrium; LGE- late gadolinium enhancement; VO2- oxygen uptake; AT- anaerobic 
threshold; OUES (VO2 ml/min / VE L/min)- oxygen uptake efficiency slope; HMR- heart 
mediastinum ratio; lnRHI- natural log of reactive hyperaemic index; AI@75bpm- 
augmentation index normalised for a heart rate of 75; mIBG meta-iodo-benzylguanidine. 
 
5.3.1 Right and Left Heart Catheterisation Data 
Right and left heart catheterisation data is presented in Table 5.2. It was not possible to obtain 
a pulmonary capillary wedge pressure (PCWP) or cardiac output using thermodilution in two 
patients. In these instances the left ventricular end-diastolic pressure (LVEDP) was used as a 
surrogate for the PCWP and the indirect Fick method was used to estimate cardiac output. 
Fifteen patients had invasive evidence of raised left ventricular filling pressures at rest (either 
PCWP≥15mmHg or LVEDP≥16mmHg).[267] Nine patients had pulmonary hypertension 
(mean PAP ≥ 25mmHg); all had a post-capillary component (raised PCWP and/or LVEDP) 
of which three also had evidence of an associated pre-capillary component (PVR>240 
dynes/sec/cm
5
 and/or TPG >12mmHg).[268] Five patients were hypertensive with an 
invasive mean artery pressure (MAP) ≥ 105mmHg and two were hypotensive with a MAP< 
70mmHg. 
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Patient 
ID 
Mean 
PAP 
(mmHg) 
Mean 
PCWP 
(mmHg) 
LVEDP 
(mmHg) 
TPG 
(mmHg) 
PVR 
(dynes/sec/cm
5
) 
MABP 
(mmHg) 
2 24 16 22 8 149 68 
4 20 15 17 5 52 109 
5 24 13 21 11 121 82 
6 28 16 21 12 168 90 
8 20 17 15 3 39 66 
9 26 24 13 2 25* 116 
10 20 11 13 9 149* 94 
11 24 19 15 5 60 105 
13 26  17 9 150 101 
15 17 14 15 3 45 76 
16 43 21 19 22 201 97 
17 46 39 22 7 126 92 
19 43 25 27 18 436 129 
21 31  22 9 124 90 
23 28 16 17 12 126 105 
24 25 22 17 3 46 74 
25 22 17 19 5 85 88 
No. 
Elevated 
9 (53%) 12 
(80%) 
12 
(71%) 
3 (18%) 1 (6%) 5 (29%) 
Table 5.2: Right and left heart catheterisation haemodynamic data for the 17 patients 
who received renal denervation therapy . Highlighted (red) are abnormally elevated 
parameters.PAP- pulmonary artery pressure; PCWP- pulmonary capillary wedge pressure; 
LVEDP- left ventricular end-diastolic pressure; MABP- mean arterial blood pressure; TPG- 
trans-pulmonary gradient; pulmonary vascular resistance. * Derived using the indirect Fick‟s 
cardiac output to rather than thermodilution cardiac output.  
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5.4 Discussion 
Over 10000 heart failure patient records had to be screened to eventually obtain the 25 
patients who agreed to take part in the trial. This reduction factor will limit the 
generalizability of any findings and has been discussed in more detail in Chapter 4. Just as 
importantly if the results of the RDT-PEF trial are positive a strategy to improve recruitment 
to make a future and substantially larger phase III study feasible needs to be devised. 
Difficulty in finding patients that satisfy the myriad of trial entry criteria has proved to be the 
tomb of many heart failure trials and in particular for HFpEF.[107, 132] 
 
Randomisation in the RDT-PEF study appears to be statistically balanced for key variables 
across the two allocation groups. There is a suggestion that the RDT group may have been 
more likely to be on diuretics, have a lower VO2 peak on cardiopulmonary exercise testing 
and have a higher BNP at baseline than the control group. These subtle differences are 
commonly encountered despite randomisation in studies with small sample sizes and can be 
statistically adjusted for using analysis of covariance (ANCOVA).[269] All patients had an 
EF ≥ 50% (using the gold standard technique of cardiac magnetic resonance imaging) 
satisfying the recent HFpEF diagnosis guidelines [7], despite the inclusion criteria EF being 
amended to >40%. 
 
RHCs of the 17 patients who were randomised to receive RDT found that the majority (88%) 
had invasive evidence of raised filling pressures and nine had pulmonary hypertension due to 
left heart disease. This suggests that the inclusion criteria used in the trial helped identify not 
only an accurately diagnosed HFpEF population but also one which occupied a position on 
the more severe end of the heart failure spectrum. Two patients did not have invasive 
haemodynamic evidence of raised left ventricular filling pressures. This is not an 
unsurprising finding and may reflect the limitations of performing static as opposed to 
dynamic assessments. Indeed saline loading and exercise (upper or lower limb) have been 
used to unmask elevated filling pressure in patients with HFpEF who have normal baseline 
PCWPs.[53, 55] These manoeuvres are yet to be standardised and validated, which is why 
they were not performed on our study population. 
 
Table 5.3 compares the baseline characteristics of the randomised RDT-PEF population to 
that of three recently conducted phase II studies in HFpEF: RELAX [153], ALDO-
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DHF[140], PARAMOUNT[154]. The populations across the four phase II HFpEF studies 
have important distinctions. The RDT-PEF population has a numerically older population, 
greater proportion of atrial fibrillation and patients receiving cardiovascular medications and 
a smaller proportion of hypertensives. The RDT-PEF patients had the highest symptoms 
scores at baseline (excluding the PARAMOUNT study which used an alternative symptom 
questionnaire). It is difficult to compare exercise performance due to different methodologies 
(protocols and equipment) used between the studies. The RDT-PEF cohort had a mildly 
reduced exercise capacity achieving on average 78% of maximum predicted peak VO2. The 
patients recruited to the RELAX study had the lowest peak VO2 as a low threshold for this 
parameter was adopted as an inclusion criterion for this trial. 
 
Despite using a different modality (CMR vs echocardiography) of imaging the indexed left 
atrial volume is greater in the RDT-PEF trial compared to the previous studies and may be 
related to the higher proportion of patients in atrial fibrillation. It is difficult to compare 
natriuretic peptide levels between the trials as the RDT-PEF trial utilised BNP (due to 
availability) whereas the others used NT-pro BNP. Nonetheless, the patients recruited into the 
RDT-PEF trial were likely to have greater natriuretic peptide levels than those that entered 
ALDO-DHF; the latter trial received some criticism of recruiting patients that were on the 
milder end of the heart failure spectrum.[270] 
 
Trialists designing future phase II trials in HFpEF have been encouraged to select phenotypes 
of patients that might match the mechanism of action of the investigational treatment,[151] 
e.g. trialing sildenafil in patients with HFpEF and pulmonary hypertension [152] rather than a 
purely volume overload phenotype.[153] Sub-selecting certain phenotypes of HFpEF though 
necessary will have a considerable (perhaps even prohibitive to single centre phase II studies) 
impact upon recruitment. This challenge might feasibly be overcome by the establishment 
and organisation of national heart failure networks capable of diagnosing and effectively 
identifying patients for future clinical study. 
 
5.4.1 Conclusion 
The RDT-PEF trial randomisation resulted in statistically balanced groups of patients with 
features of advanced HFpEF. The laborious screening process, with a small minority of 
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patients eligible for randomisation preclude the application of the results of this study to the 
majority of patients with HFpEF and especially those with less severe features. 
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Variable 
ALDO-DHF 
[140] RELAX [153] 
PARAMOUNT 
[154] RDT-PEF 
Number 422 216 301 25 
Age (years) 67 ± 8 69 (62-77) 71.1 ± 9.2 74.3 ± 6.1 
Male 201 (47.6%) 112 (51.9%) 131 (43.5%) 15 (60.0%) 
LV EF (%) 67 ± 8 (Echo) 
66 (59-71) 
(MRI) 58.1 ± 8 (Echo) 
66.3 ± 9.1 
(MRI) 
Past Medical History 
Diabetes 70 (16.6%) 93 (43.1%) 114 (37.9%) 10 (40.0%) 
Hypertension 387 (91.7% 183 (84.7%) 282 (93.7%) 18 (72.0%) 
CHD 170 (40.3%) 84 (38.9%) 62 (20.6%)
#
 6 (24.0%) 
COPD 14 (3.3%) 42 (19.4%) 
 
6 (24.0%) 
AF 22 (5.2%) 111 (51.4%) 85 (28.2%) 15 (60.0%) 
Medications 
ACEi 
325 (77.0%) 152 (70.4%) 
163 (54.2%) 
23 (92.0%) 
ARB 119 (39.5%) 
ARA 0 (0%) 23 (10.6%) 63 (20.1%) 6 (24.0%) 
BB 302 (71.6%) 164 (75.9%) 238 (79.1%) 18 (72.0%) 
Loop diuretic 227 (53.8%) 166 (77.3%) 301 (100%) 21 (84.0%) 
RDT-PEF Primary Endpoints 
MLWHFQ 22 ± 16 43 (30-62) Not done 47 (25-54) 
Peak VO2 
(ml/Kg/min) 
16.4 ± 3.5 
(Bike) 
11.7 (10.2-14.4) 
(Bike/treadmill) Not done 
15.6 ± 3.6 
(Treadmill) 
NT-proBNP 
(ng/L) 158 (83-299) 700 (283-1553) 828 (460-1341)* 
184 (128-282) 
(BNP) 
E/e’ 
12.8 ± 4.0 
(medial) 
17 (12-24) 
(medial) 
12.8 ± 7.8 
(lateral) 
13.8 ± 5.3 
(average) 
LAVI (ml/m
2
) 28.0 ± 8.4 (E) 43 (38-59) (E) 36.2 ± 13.5 (E) 
62.3 ± 28.1 (M) 
48.4±14.4 (E) 
LVMI (g/m
2
) 117 ± 31 (E) 
61 (53-73) (M) 
77 (62-96) (E) 78± 21 (E) 
63.4 ± 10.4 (M) 
107 ± 30 (E) 
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Table 5.3: Comparison of key baseline features between phase II studies and the RDT-
PEF trial . Continuous variables are presented as mean ± standard deviation or median 
(quartile 1- quartile 3). CHD- coronary heart disease; COPD- chronic obstructive airways 
disease; AF- atrial fibrillation; ACEi- angiotensin converting enzyme inhibitor; ARB- 
angiotensin receptor blocker; ARA- aldosterone receptor blocker; BB- beta-blockers; eGFR- 
estimated glomerular filtration rate; 
#
 myocardial infarction; * placebo group; MLWHFQ- 
Minnesota Living with Heart Failure Questionnaire; (E)- echo; (M)- cardiac magnetic 
resonance imaging. 
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6 Description of the renal artery ablation performed in the 
RDT-PEF patients  
 
6.1 Introduction 
It has been suggested that the number of renal artery ablations performed and whether they 
are circumferentially sited may be important determinants of the effect of RDT.[271] In this 
chapter I will summarise important intra-procedural data obtained in the seventeen patients 
who underwent RDT in the RDT-PEF trial. 
 
6.2 Methods 
These have been described in detail in chapter 3. An ablation point was counted as 
successfully if a >10% drop in impedance and/or a temperature of ≥ 50◦C were recorded at 
the electrode tip following a 120 second energy application. An anatomically complete 
ablation was defined as at least: two successfully ablations in the lateral wall (one anterior, 
one posterior), one in the superior wall and one in the inferior wall. During the procedure, a 
nurse prospectively collected the details of the ablation delivered and would provide feedback 
to the operators if insufficient ablations had been performed. 
 
Data are presented as mean ± standard deviation or median (interquartile range) depending on 
their distribution.  
 
6.3 Results 
6.3.1 Renal Denervation Technique 
Sixteen patients underwent RDT by HP and CDM and one patient by HP and RDS. Data 
regarding total procedure and fluoroscopy time (including right and left heart catheterisation 
and renal denervation), contrast use, analgesia and sedation administration are presented in 
Table 6.1. The data are presented in sequential order; there is no trend to suggest that with 
increasing experience there was a change in procedure or fluoroscopy time.  
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Patient ID Procedure 
Time (mins) 
Fluoroscopy 
Time (mins) 
Contrast 
(ml) 
Morphine 
(mg) 
Midazolam 
(mg) 
2 108 23 200 10 8 
4 137 26 195 5 5 
5 125 25 255 10 5 
6 170 38 210 13 4 
8 220 34 200 18 5 
9 220 59 230 6 3 
10 136 26 220 10 3 
11 153 23 250 9 6 
13 160 37 400 9 5 
15 146 22 180 12 4 
16 178 34 220 5 4 
17 140 37 170 7 9 
19 176 29 180 4 3 
21 153 40 155 9 13 
23 120 28 230 5 3 
24 120 24 170 5 3 
25 190 54 230 6 3 
Mean ± SD 156 ± 33 33 ± 11 217 ± 55 8 ± 4 5 ± 3 
Table 6.1: Renal denervation procedural details.  
 
Table 6.2 details the number and location of successful ablations applied for each of the 17 
patients. All patients had a minimum of four (median 5) successful ablations to each 
attempted artery. Across both arteries the average number of ablations delivered was: median 
10 (9, 11); mean 9.9 ±1.7. No ablation was feasible to the left renal artery of patient 9 due to 
inability to achieve a stable guide catheter position because of the acute angle at which the 
origin of the left renal artery arose from the aorta (Figure 6.1). In this case a Guidezilla™ 
(Boston Scientific, USA) extension catheter together with over the wire microcatheters and 
various wires were also used but without success. The short length of the Symplicity™ 
catheter prevented an alternative approach from the left brachial artery. Twelve patients had 
incomplete circumferential ablations, whereby radiofrequency energy was not successful 
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applied to all quadrants. This occurred despite best efforts of the operators, however, it was 
not always possible to maintain stable apposition of the radiofrequency electrode to the 
relevant quadrant of the arterial wall. 
 
Patient 
ID 
No. Right Renal Artery Ablations No. Left Renal Artery Ablations 
Sup Inf Lat Total Sup Inf Lat Total 
2 0 3 1 4 3 0 1 4 
4 2 1 1 4 2 2 1 5 
5 2 2 1 5 3 1 1 5 
6 1 2 1 4 2 2 2 6 
8 1 1 2 4 2 1 2 5 
9 3 1 2 6 0 0 0 0 
10 2 1 1 4 3 1 2 6 
11 0 2 2 4 2 2 2 6 
13 2 2 2 6 2 1 2 5 
15 2 1 2 5 3 2 1 6 
16 2 1 3 6 1 1 2 4 
17 2 3 1 6 2 2 1 5 
19 3 2 1 6 2 2 3 7 
21 1 1 2 4 2 1 2 5 
23 2 3 2 7 2 3 1 6 
24 1 2 2 5 1 3 1 5 
25 1 3 1 5 2 1 1 4 
Median 
(IQR) 
2 (1, 2) 2 (1, 2) 1 (1, 2) 5 (4, 6) 2 (2, 2) 1 (1, 2) 1 (1, 2) 5 (5, 6) 
Table 6.2: Number and pattern of radiofrequency energy applications in the RDT-PEF 
trial . Highlighted (green) are patients who had an anatomically complete ablation. Sup- 
superior; Inf- inferior; Lat- lateral; IQR- interquartile range. 
 
Achieving an adequate level of analgesia was difficult in patient 8 and 21. Doses of opioids 
and sedatives had to be greatly uptitrated during the procedure. An anaesthetist was called to 
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assist with these two patients and the procedure was completed without the need for general 
anaesthesia and without the need for any opioid or benzodiazepine reversal agents. 
 
 
Figure 6.1: Renal artery images of patient 9 . Magnetic resonance angiography on left and 
invasive renal artery angiography on the right. The left renal artery arises at an acute angle 
from the aorta.  
 
6.4 Discussion 
There were no trends to suggest a learning curve with RDT when analysing procedural time, 
fluoroscopy time, contrast use or total number of ablations applied. This is not surprising as 
the senior two operators in our department had more than two years of experience in 
performing RDT procedures in resistant hypertension prior to commencement of the trial, 
significantly greater than the prior experience of the interventionists who participated in 
SYMPLICITY HTN-3.[199] 
 
An important Achilles‟ heel of the RDT procedure is that currently it is unknown what 
constitutes an adequate attenuation of the renal sympathetic nerves and furthermore there 
remains no intra-procedural marker of success. Efforts to address the latter are underway and 
include the measurement of haemodynamic responses to renal nerve stimulation before and 
immediately after ablation.[112, 167, 272] However, until a validated technique is established 
it is difficult to ascertain in cases of treatment failure whether the underlying factor was 
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inadequate ablation. In the interim, number of ablations applied in each patient has been 
widely used as a surrogate marker.[199, 273] 
 
In the RDT-PEF study, the mean number of ablations applied per patient was 9.9 and this 
compares to 11.5 from the Global SYMPLCITY registry [273] and 9.2 from SYMPLICITY 
HTN-3.[199] Five patients (29.4%) received an anatomically complete denervation involving 
all four quadrants, which though better than the 6% (19/340) achieved in the SYMPLICITY 
HTN-3 trial, highlights that administration of radiofrequency energy with a single electrode 
catheter is cumbersome and not consistent.[271] Improvement in catheter design, with the 
advent of multi-electrode systems ( Table 2.2) may improve ease by which anatomically 
complete denervations can be consistently achieved but this remains to be proven. 
 
During the course of this PhD, further human histology data was published which brought 
under scrutiny the original recommended RDT procedure.[158] The important findings from 
that group were: 
 
I. The nerves approximate closer to the renal artery lumen as they progress from the 
aorta to the renal hilum. Prior to any renal artery bifurcation, 90% of the renal nerves 
are within 6.4 mm of the renal artery lumen. However, after any bifurcation, 90% of 
the nerves are within 3 mm of the lumen. 
II. The number of nerves is greater around the proximal and middle segments of the renal 
artery than the distal. 
III. A larger proportion of nerves pass anterior, superior, and inferior to the renal artery as 
opposed to posterior to it. 
 
There is limited published data describing the penetration depth of the Symplicity™ catheter 
but it is estimated to be 2-4mm.[274-276] This suggests that RDT limited to proximal 
segments of the renal artery prior to any bifurcation (original recommended technique) may 
not adequately attenuate the renal SNS adequately and that perhaps a better strategy might be 
to perform distal renal artery ablation at more than 4-6 unique sites with catheters capable of 
generating deeper injury.[277] The third generation RDT catheters now available may be 
more efficacious and consistent, which may have a significant bearing on trial outcomes if 
many of the RDT trials that had originally used the now largely defunct Symplicity™ 
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catheter were repeated. Notably, the Spyral™, Vessix™, EnligHTN™, Paradise™, 
Renlane™, and Peregrine™ systems allow easier circumferential/helical denervation due to 
either multiple ablation electrodes or multiple alcohol injection needles; the Spyral™ and 
Vessix™ system allow even more distal ablation down to vessel diameter of 3mm (compared 
to 4mm for the others); and Paradise™ and Peregrine™ have shown to have a greater depth 
of penetration.[275, 278, 279] 
 
6.4.1 Conclusion 
Although the minimum recommended numbers of ablations were applied in almost all of the 
patients approximately 70% did not receive a successful circumferential four quadrant 
ablation. If the RDT-PEF trial reports negative results, inadequate renal artery ablation may 
be a contributory factor. 
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7 Primary Efficacy and Safety Outcomes of the RDT-PEF study 
 
7.1 Introduction 
The background to the RDT-PEF study has been detailed in Chapters 1&2. 
 
I hypothesized that targeting the renal sympathetic nerves would improve symptoms and 
exercise performance and induce functional and structural cardiac remodelling. 
 
7.2 Methods 
These have been described in Chapter 3.  
 
7.2.1 Statistics 
Further to the primary efficacy and safety endpoint statistical plan described in Chapter 3, 
secondary analyses have been undertaken. The latter included an individual-level analysis 
whereby each patient‟s baseline value was compared with their 3 and 12-month value across 
the six primary end points and the patients‟ responses were scored as: +1 for improvement, -1 
for deterioration and 0 for no change using the thresholds detailed in the sample size. [248] 
Improvements were defined as: Minnesota Living with Heart Failure questionnaire score 
(MLWHFQ): -10; peak oxygen uptake (VO2): +1.5 mg/ml/Kg; B-type natriuretic peptide 
(BNP): -50 ng/L; E/e‟: -2; left atrial volume index (LAVI): -4ml/m2; left ventricular mass 
index (LVMI): -5g/m
2
.  
 
Spearman‟s rank correlation coefficient was used to assess any association between the 
number of successful ablations performed and changes in the efficacy endpoints and 
estimated glomerular filtration rate (eGFR). Mann-Whitney U- test was used to contrast the 
change in the efficacy endpoints between those patients who received an anatomically 
complete denervation to those who did not. Medication changes (limited to angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, alpha-blockers, 
diuretics, aldosterone antagonists, calcium-channel blockers and digoxin) were compared 
using the χ2-test. For the secondary analyses a P<0.05 was deemed statistically significant, 
which is stricter to the threshold adopted for the primary analyses described in Chapter 3. 
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7.3 Results 
The baseline characteristics of the 25 recruited patients have been described in Chapter 5.  
 
7.3.1 Efficacy Endpoints 
At three months follow up there were significant (using p<0.2 as the pre-specified threshold) 
improvements in the RDT group compared to the control group with respect to peak VO2 on 
exercise and E/e‟ on echocardiography (Table 7.1), however this did not fulfil the pre-
specified trial success criteria requiring an improvement in a minimum of three endpoints 
(Figure 7.1). At 12 months there were no significant changes with any of the primary 
endpoints. 
 
On secondary analysis, there was an improvement in the composite efficacy score at the 3 
months in the RDT group compared with control (P=0.018) but not at 12 months (P=0.921) 
(Figure 7.2). This signal for an early effect was driven by a greater proportion of patients that 
improved by the pre-specified clinically significant amount in the RDT group than in the 
control group with respect to VO2 peak (56% vs 13%, P=0.025) and E/e‟ (31% vs 13%, 
P=0.04) (Figure 7.1).  
 
7.3.2 Safety Endpoints 
There were no deaths, peri-procedural strokes or myocardial infarctions during the course of 
the study. No patients developed symptomatic hypotension. Two patients in the RDT group 
experienced a greater than 30% reduction in eGFR at 12 months compared to baseline. On 
renal artery magnetic resonance angiography (MRA) there was no evidence of new renal 
artery stenosis in these patients. The median change in eGFR at 12 months was not different 
between the two study groups (-3 ml/min/1.73m
2
 [-11, 3] vs 4 ml/min/1.73m
2
 [-8, 5], 
p=0.318). 
 
Peri-procedurally there were no femoral artery complications. Two patients developed 
intense renal artery spasm/oedema during the ablation procedure. These were acutely treated 
with intra-arterial nitrate. As the vessel reactions persisted after 20 minutes of waiting, 
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angioplasty (without stent deployment) was performed at these sites, with visually 
satisfactory responses to vessel diameter. These vessels remained patent at 12 months when 
assessed by MRA.  
 
Three patients developed progression (not requiring invasive intervention) of existing renal 
artery atheroma during the study period (two in control arm, one in active arm). Three 
patients were admitted with decompensated heart failure (two in the RDT group, one in the 
control group). Two patients underwent coronary revascularisation between the three and 12 
months (one in each group). 
 
7.3.3 Subgroup analysis based upon number and distribution of ablations 
In those patients that received RDT, there were no correlations between the total numbers of 
ablations applied and the change in primary efficacy endpoints at 3 or 12 months follow-up 
or the change in eGFR. The five patients who received anatomically complete denervation 
had no greater improvements at three month or 12 month follow-up compared to the 12 
patients who did not (Table 7.2). 
 
7.3.4 Medication Changes 
There were no statistical differences between the proportions of patients who had their 
medications altered in either allocation group (Table 7.3). Compared to baseline, at 12 
months, eight patients in the active arm had their medication doses increased and three in the 
control arm, whereas six patients in the active arm had their doses decreased compared with 
four in the control arm.  
 
7.4 Discussion 
This is the first report of a randomised controlled trial examining the role of RDT in patients 
with HFpEF to complete. The primary efficacy endpoint of the trial was not met and there 
were no significant improvements seen with RDT with respect to heart failure symptoms, 
peak VO2 on exercise, BNP, E/e‟ on echocardiography, left atrial volume index or left 
ventricular mass index at 12 months. Renal function did not change significantly between the 
active and control arms. 
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The study end-points constitute those recommended for phase II studies [244-247] and the 
study population sits on the more advanced end of the heart failure spectrum similar to 
recently published trials (Table 5.3). In the presence of a negative trial it is fair to challenge 
the strength of the rationale and the appropriateness of the therapeutic intervention. It is also 
important to reconsider the adequacy of the statistical plan to identify differences that might 
be less striking than expected but still clinically relevant. If we start with the latter point and 
assume that the trial is conclusive then it would be unethical continuing similar on-going 
studies.  
 
Though the RDT-PEF trial failed to meet its primary endpoints, it was underpowered to do so 
(85% power required a sample size of 36 patients, compared to the 25 actually recruited). A 
larger study is required and pooling of data sets with the two other currently on-going and 
similar phase II studies (DIASTOLE and RESPECT HF) might be helpful. Interestingly, at 
three months there was a strong signal of benefit to those allocated to RDT in particular with 
respect to improvement in BNP and E/e‟. There are two possible explanations for this 
discrepancy in response between three and twelve months. The first consideration is the 
Hawthorne effect, whereby patients who are pleased to be allocated to the RD group might 
make more effort in the cardiopulmonary exercise test thereby increasing the peak VO2.[280] 
It is likely that this bias would wane with time. The other possibility is sympathetic nerve 
regrowth. In sheep denervated with the Symplicity™ catheter, functional and anatomical 
regeneration of the afferent and efferent sympathetic nerves was seen at 11 months.[164] 
These findings reinforce the importance of blinding and staged analyses to look for early and 
late benefit. The latter is particularly important as it is not possible to quantify the degree of 
sympathetic denervation or re-innervation accurately following RD in humans. 
 
There should remain clinical equipoise regarding the role of RDT in HFpEF; however, there 
remain uncertainties about the prevalence of SNS over-activity in HFpEF and the degree of 
sympathetic nervous system (SNS) modulation consistently achievable with RDT. The 
evidence supporting an elevated SNS activity in heart failure is more established in the 
HFrEF rather than the HFpEF population and has been summarised in Chapters 1&2.[87] The 
maladaptive influences of the SNS at the cardiac, renal and peripheral vasculature level are 
likely to negatively affect HFpEF patients. Several trials are addressing the usefulness of 
renal denervation in heart failure but none have gone beyond the recruitment phase, with the 
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initial report only addressing safety.[169, 238, 281] Though the negative results of the RDT-
PEF trial sits in good company with the unexpected negative results of two recent randomised 
sham-controlled trials of RDT in resistant hypertension, it is important to remember two 
pivotal differences between the studied diseases.[199, 200] Firstly, the prognosis is 
significantly worse in patients with HFpEF compared to those with hypertension [35] and 
secondly the nature of SNS activation is different between the two conditions.[282] 
 
Doubt in the efficacy of RDT in attenuating the harmful renal responses to SNS stimulation 
were raised following the publication of two randomised-controlled blinded trials examining 
the role of RDT in resistant hypertension.[199, 200] Two widely discussed factors underlying 
the neutral results of these trials include: 1. the ablation performed was inadequate and 2. the 
wrong patients were selected. Difficulties in performing an anatomically complete ablation 
using the Symplicity™ catheter are discussed in Chapter 6. Nonetheless, our cohort of 
patients who underwent denervation was five times more likely to have received a complete 
anatomical ablation than those recruited into SYMPLICITY-HTN 3. In subgroup analysis 
there was no association between number/completeness of ablations (a non-validated 
surrogate measure for proportion of renal sympathetic nerves attenuated) and 
effectiveness/safety endpoints.  
 
HFpEF remains a diagnosis of exclusion and is an umbrella term for different phenotypes of 
heart failure in the presence of a preserved ejection fraction.[155, 283] Ideally the phenotype 
with an elevated SNS should have been selected for the RDT-PEF trial. However, in the 
absence of a gold-standard technique to measure the SNS this would have been difficult and 
very likely to have made recruitment to the trial in a single-centre setting excessively 
prohibitive. Baseline assessments of the autonomic nervous system and their response to 
RDT in our trial population are discussed in Chapter 5. 
 
Consistent with the broader literature, which almost exclusively pertains to the Symplicity™ 
catheter and patients with resistant hypertension, RD in patients with HFpEF appears safe up 
to 12 months of follow-up. However, it is not without risk, with two patients requiring low 
pressure balloon angioplasty to treat intense vessel spasm/oedema, and improve distal 
perfusion a complication which has been reported previously.[284] Twelve month renal 
magnetic resonance angiography in these patients did not reveal any new stenosis at these 
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sites. Two different patients had a decline in eGFR>30%; further clinical follow-up data was 
available to us and these patients‟ eGFR recovered to pre-randomisation levels after 
completing treatment for fluid overload. 
 
7.4.1 Limitations 
The strengths of the RDT-PEF trial are that it is randomised and controlled and presents data 
on the largest population of patients with HFpEF studied to date. It is a single centre 
experience and hence its results may not be generalizable. Furthermore the trial findings are 
subject to bias as it was a non-blinded trial without a sham procedure. Efforts were 
undertaken to address this by having observers blinded to allocation analyse the collected 
data. This is likely to avoid most of the biases reported from the earlier randomised-
controlled trials of RDT in resistant hypertension but remains susceptible to bias when 
handling subjective endpoints such as symptom questionnaires.[201, 280] The primary 
outcomes of the study were all neutral and any conclusions drawn from the secondary 
analyses should only be considered hypothesis generating. The results pertain to the efficacy 
of the single electrode Symplicity™ catheter system that many consider to be obsolete now 
that multi-electrode catheters have been developed. 
 
7.4.2 Conclusions 
Renal denervation can be safely performed in patients with HFpEF though not without 
complication. No significant effect on multiple endpoints encompassing quality of life, 
function, biomarkers and cardiac remodelling was observed. A possible signal of effect was 
seen at three months but this was not sustained at 12 months. A larger study is required, 
which would benefit from a co-ordinated effort across multiple heart failure networks to 
overcome the challenges in recruitment, and the use of multiple-electrode catheter systems. 
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 RDT Control Change from baseline 
 Baseline 
(n=17) 
3 
Months 
(n=16) 
12 
Months 
(n=17) 
Baseline 
(n=8) 
3 
Months 
(n=8) 
12 
Months 
(n=7) 
3 Months 12 Months 
RDT Control P P* RDT Control P P* 
MLWHFQ 48 (27-
56) 
38 (30-
46) 
35 (27-
50) 
28 (25-
50) 
35 (16-
42) 
25 (14-
36) 
-9 (-
15, 
10) 
-6 (-12, 
6) 
0.988 0.699 -7 (-
20, 
4) 
-7 (-10, 
0) 
0.721 0.708 
VO2 Peak 
(ml/Kg/min) 
14.7 ± 
3.3 
15.9 ± 
4.1 
14.0 ± 
3.2 
17.5 ± 
3.8 
16.8 ± 
5.4 
18.1 ± 
5.3 
+1.4 
± 1.9 
-0.7 ± 
4.4 
0.112 0.150 +0.2 
± 2.0 
+0.8 ± 
4.3 
0.637 0.472 
BNP (ng/L) 210 
(137-
354) 
234 
(133-
327) 
215 
(142-
351) 
149 (99-
205) 
183 
(90-
283) 
125 
(112-
262) 
-19 
(-59, 
54) 
+28 (-
26, 124) 
0.257 0.763 -3 (-
59, 
33) 
+18 (-2, 
30) 
0.318 0.559 
E/e’ 
(average) 
14.6 ± 
6.7 
12.3 ± 
4.5 
14.0 ± 
6.6 
14.4 ± 
3.9 
16.7 ± 
2.3 
13.9 ± 
3.4 
-1.1 
± 5.7 
+2.3 ± 
3.1 
0.123 0.015 +0.2 
± 4.4 
+0.2 ± 
1.2 
0.974 0.962 
Left atrial 
volume 
(ml/m
2
) 
62.8 ± 
29.2 
64.9 ± 
30.1 
69.3 
±32.5 
61.3 ± 
21.7 
65.1  
26.7± 
60.7 ± 
36.1 
+1.3 
± 8.8 
-1.3 ± 
8.2 
0.495 0.518 +6.5 
± 
13.2 
+2.4 ± 
8.9 
0.461 0.504 
LV mass 
(g/m
2
) 
62.9 ± 
11.4 
62.9 ± 
11.8 
63.5 
±12.4 
64.6 ± 
7.1 
63.4 ± 
6.0 
65.3 ± 
7.2 
+0.4 
± 2.8 
-1.1 ± 
2.7 
0.214 0.250 +0.7 
± 4.3 
+0.2 ± 
3.2 
0.803 0.807 
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Table 7.1 Primary efficacy endpoints at baseline, 3 months and 12 months. Data are 
presented as mean ± standard deviation or median (quartile 1, quartile 3). P- represent 
unadjusted independent samples t-test or Mann-Whitney U test. P* -values are adjusted for 
baseline values using an ANCOVA model. LV- left ventricular
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Endpoints Change at 3 months from 
Baseline 
Change at 12 months from 
Baseline 
Complete 
Ablation 
(n=5) 
Incomplete 
Ablation 
(n=12) 
P Complete 
Ablation 
(n=5) 
Incomplete 
Ablation 
(n=12) 
P 
Efficacy 
MLWHFQ +8 (-27, 
20) 
-10 (-15, 4) 0.446 -20 (-22, 
1.5) 
-4 (-13, 5) 0.234 
VO2 Peak 
(ml/Kg/min) 
+2.6 ± 1.5 +1.0 ± 1.9 0.262 1.3 ± 1.9 -0.2 ± 4.6 0.343 
BNP (ng/L) +37 (-9, 
54) 
-33 (-63, 
66) 
0.212 +20 (-47, 
49) 
-21 (-81, 
13) 
0.383 
E/e’ (average) -5.2 ± 7.4 +0.2 ± 4.6 0.133 -0.3 ± 6.9 +0.4 ± 3.2 0.646 
Left atrial 
volume (ml/m
2
) 
+1.8 ± 8.2 +1.2 ± 9.3 0.862 +10.5 
±13.3 
+4.9 ± 13.4 0.506 
Left ventricular 
mass (g/m
2
) 
+1.8 ± 2.9 -0.1 ± 2.8 0.316 +1.6 ± 2.5 +0.3 ± 4.9 0.721 
Safety 
eGFR 
(ml/min/1.73m
2
) 
-6 (-7, -4) -3 (-11, 3) 0.599 -2 (-12, 5) -3, (-11, 3) 0.879 
Table 7.2: Subgroup analyses comparing change in efficacy endpoints and eGFR 
between those patients that received anatomically completed ablation and those with 
incomplete . Data are presented as mean ± standard deviation or median (quartile 1, quartile 
3). p represents Mann-Whitney U test. 
 
Medication 
Doses 
Three Months Twelve Months 
Altered No Change Altered No Change 
RDT Patients 8 8 11 6 
Control Patients 3 5 4 3 
P (χ2) 0.679 1.000 
Table 7.3: Number of patients who had medication alterations during the course of the 
RDT-PEF trial 
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Figure 7.1: Primary efficacy endpoints for the RDT-PEF trial 3 and 12 months . The 
brown dotted lines represent the threshold for a clinically significant change. 
MLWHFQ- Minnesota Living with Heart Failure Questionnaire; Peak VO2- maximum 
oxygen uptake on exercise treadmill; BNP- B-type natriuretic peptide; LAVi- left atrial 
volume index; LVMi- left ventricular mass index. 
 
 
 
 
Figure 7.2 Clinically meaningful change composite patient score. Numbers in each filled 
circle correspond to an individual patient. Summary lines represent mean with standard error. 
P values derived from independent samples t-test. 
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8 The effect of renal denervation on vascular function in the 
patients recruited to the RDT-PEF trial 
 
8.1 Introduction 
As discussed in Chapter 1, the pathophysiology of HFpEF is multifactorial and includes 
abnormal ventricular-arterial coupling.[48, 67, 75, 285] This term includes both macro and 
micro vascular abnormalities both of which have been demonstrated in patients with 
HFpEF.[68, 74, 286-288] There is limited data to suggest that abnormal vascular function in 
HFpEF is associated with increased cardiovascular events.[74, 289] 
 
The sympathetic nervous system (SNS) is a modulator of arterial function and as such may be 
an important target in heart failure.[85, 104, 174, 290-292] Renal denervation therapy (RDT) 
is a novel technique that has been shown to reduce central sympathetic outflow and hence 
may promote vascular remodelling.[220, 221, 293]    
 
We investigated the effect of RDT on macro and microvascular function in HFpEF, using an 
array of non-invasive assessments: 24 hour ambulatory blood pressure monitoring (24hr 
ABPM), aorta distensibility, pulse wave velocity, reactive hyperaemia index and 
augmentation index, including some more specific markers for the renal vessels (renal artery 
flow, resistive index, pulsatility index, albuminuria). 
 
8.2 Methods 
All patients enrolled into the RDT-PEF trial were also included in the vascular function sub-
study. Methodological details for 24hr ABPM, aorta distensibility and pulse wave velocity 
measurement using MRI, reactive hyperaemia and augmentation index assessment using 
EndoPAT™, renal blood flow, renal artery resistive index, renal artery pulsatility index using 
renal MRI and estimation of albuminuria are provided in Chapter 3. 
 
These variables are measured on a continuous scale and for the majority normal cut-off 
values have not been derived. Abnormal vascular function is associated with an increased 
pulse pressure, pulse wave velocity, augmentation index, resistive index, pulsatility index, 
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albuminuria (albumin:creatinine > 30mg/g) and a decreased aorta distensibility and reactive 
hyperaemia index (Ln RHI≤ 0.51). 
 
8.2.1 Statistics 
Data were assessed for normality both subjectively using histograms and statistically using 
the Shapiro-Wilk test. Parametric data are presented as mean ± standard deviation; between 
group comparisons were performed using the independent samples t-test and within group 
comparisons using the paired t-test. Non-parametric data are presented as median with 
interquartile range; between group comparisons were performed using the Mann-Whitney U 
test and within group comparisons using the Wilcoxon-signed rank. Correlation between 
parameters was assessed using Spearman‟s rho. P<0.05 was used as the threshold for 
statistical significance. A P<0.01 was used for the multiple correlation assessments. 
 
8.3 Results 
8.3.1 Ambulatory Blood Pressure Monitoring 
At baseline, nine patients (two were in control arm) were hypertensive and had a 24hr 
ambulatory systolic blood pressure (SBP) reading ≥ 130 mmHg and one patient had an 
average SBP <100mmHg (in RDT arm). There were no between group differences in 
ambulatory blood pressure changes at three months and 12 months after RDT (Table 8.1, 
Figure 8.1). There was no significant correlation between baseline 24hr average systolic 
blood pressure and change at three months (r= -0.46, p=0.361) or 12 months (r= -0.05, 
p=0.923) in the seven patients who had baseline averages ≥ 130 mmHg and were allocated to 
denervation (Figure 8.1). 
8.3.2 Macrovascular and Microvascular Function 
Table 8.2 details the findings. At baseline 15 patients (12 RDT, 3 Control) had a LnRHI≤ 
0.51 and 10 patients (8 RDT, 2 Control) had an ACR>30mg/g. RDT did not improve any of 
the measured markers of vascular function at three or 12 months follow up. 
 
8.3.3 Renal Blood Flow 
At baseline the average blood flow per kidney was 0.22 ± 0.06 l/min, pulsatility index was 
1.89 (1.43, 2.99) and resistive index was 0.87 ± 0.09. At 12 months RDT did not result in a 
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change in renal blood flow, resistive index or pulsatility index as assessed by MRI (Table 
8.3). 
 
8.3.4 Effects of Age on Vascular Function 
There was a trend for age to be associated with baseline ascending aorta strain (rho=-0.46, 
p=0.02) and distensibility (rho=-0.42, p=0.04) as well as descending aorta strain (rho=-0.45, 
p=0.03). No correlations were seen with any of the other parameters. 
 
8.3.5 Correlations between Baseline Vascular Function and Primary Endpoints and 
eGFR 
At baseline patients with higher pulse pressures reported worse symptoms on questionnaire 
assessment and lower peak oxygen uptake on exercise (Table 8.4). In those patients who 
underwent right heart catheterisation, there were similarly no correlations been left 
ventricular end-diastolic pressure or pulmonary capillary wedge pressure and the various 
vascular parameters. 
 
8.4 Discussion 
The main finding of this body of work is that RDT did not improve vascular function in 
patients with HFpEF. It is therefore important to review: 1) the evidence supporting the initial 
hypothesis that vascular dysfunction plays an important role in HFpEF and 2) whether 
vascular dysfunction in HFpEF can be improved. This discussion remains largely academic 
and hypothesis generating as the RDT-PEF trial failed to meet its primary endpoint, the 
underlying reasons of which were discussed in Chapter 7. 
 
The literature promoting the biological plausibility of both large and small vessel dysfunction 
driving HFpEF has been extensively reviewed.[10, 294] Increased arterial stiffness predicts 
incident cardiovascular dysfunction including hypertension, heart failure and peripheral organ 
damage [295-298]. In heart failure an association between increased stiffness and premature 
death has been studied and demonstrated albeit predominately in the reduced ejection fraction 
cohort.[299-302] Ageing is associated with a decrease in the elasticity of large conduit blood 
vessels,[303] however, this decline is accelerated in patients with HFpEF.[73, 288] Indeed in 
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the RDT-PEF population, age trended with pulse pressure, a crude index of large artery 
stiffness.[294] 
 
Increased myocardial wall stress, systolic and diastolic dysfunction, left ventricular 
hypertrophy and left atrial dilatation [72, 288, 304-307] are commonly observed 
consequences of increased arterial stiffness and these features mirror those seen in patients 
with HFpEF.[48] Furthermore, aorta stiffening in selected populations of HFpEF is correlated 
positively with natriuretic peptide level and negatively with peak oxygen uptake on 
exercise.[286, 305, 308] Similarly in the RDT-PEF cohort, pulse pressure was correlated with 
heart failure symptoms and exercise performance. 
 
The large conduit blood vessels function to transform pulsatile flow generated from the heart 
to a continuous uniform flow at a lower pressure throughout systole and diastole enabling 
downstream organ perfusion.[309] Arterial stiffness shifts the transition point from pulsatile 
flow to continuous, distally from the macrovasculature to the microvasculature, which causes 
end-organ damage and has been extensively demonstrated in the kidneys.[310] This is 
important, as HFpEF is a condition driven by both cardiac and non-cardiac pathology.[10, 
311, 312] 
 
Based on these previously published data, it is appropriate to hypothesize that therapies to 
reverse arterial stiffness and improve ventricular-arterial coupling might be beneficial in 
patients with HFpEF.[285, 308] In heart failure (both HFpEF and HFrEF), neurohumoral 
activation (including the SNS) and inflammation leading to endothelial dysfunction have 
been identified as explanatory mechanisms (and hence targets) for increased vascular 
stiffness.[10, 308] 
 
Randomised controlled trials in HFpEF have failed to identify an intervention that can 
improve aorta stiffness in patients with HFpEF. Therapies investigated to date include 
angiotensin-converting-enzyme inhibitors [313], alagebrium [314], sildenafil [315] and 
exercise training [316]. The RDT-PEF trial joins this long list of neutral trials, though being 
underpowered was a significant limitation. 
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An important observation is that all these trials have used different modalities (invasive 
pressure catheters, echocardiography, magnetic resonance, tonometry, oscillometric cuffs) as 
well as different parameters (carotid femoral PWV, carotid-radial PWV, brachial-ankle, 
PWV, ascending-thoracic aorta PWV, aorta distensibility, augmentation index, reactive 
hyperaemic index, albuminuria) to measure arterial stiffness and function. The difficulty with 
this is that each combination has varying repeatability and furthermore provides a different 
insight into the macro and micro vasculature function that are not comparable. Addressing 
this issue, the American Heart Association have recently published a guidance document on 
how to assess arterial stiffness in research.[317] This document promotes the carotid-femoral 
PWV technique for non-invasive assessment of arterial stiffness. Though this is valuable 
guidance it is sobering to note that using data from the RDT-PEF cohort, approximately 268 
patients in each arm would need to be recruited for an intervention to detect a 15% change in 
PWV (80% power, p=0.05, standard deviation 6.2 m/s), which for many research units 
seeking to investigate a HFpEF population might be prohibitive. 
 
It is possible that arterial stiffness is not an ideal endpoint to use in an HFpEF clinical trial. 
The majority of the evidence showing that an intervention can improve arterial stiffness has 
been in the context of hypertension trials [318]; it is unknown whether the aorta can be 
„unstiffened‟ independent of a blood pressure reduction.[317] Also, patients recruited into 
HFpEF trials tend to be older than those in hypertension trials and consequently reversal of 
aorta stiffening with an intervention may take longer to manifest (requiring prolonged trial 
follow-up) or may be impossible reflecting an irreversible stage of the disease process.   
 
We have demonstrated that RDT did not have an effect on blood pressure up to 12 months of 
follow-up, which is an important safety finding as the majority of patients with heart failure 
are not hypertensive. This has previously only been demonstrated in an uncontrolled study of 
seven patients with heart failure and reduced ejection fraction at 6 months follow-up.[238] 
 
Finally, improvement in renal blood flow is one of the purported mechanisms of action of 
RDT. In 9 pigs, Tsioufis and colleagues showed that RDT both acutely and chronically after 
a month increased renal blood flow and reduced resistive index, assessed by an invasive 
Doppler wire.[319] We were not able to reproduce this finding in 25 humans using spiral 
renal MRA. Similarly in resistant hypertension, improvements in renal perfusion and 
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oxygenation as assessed by MRI have not been demonstrated following RDT.[220, 229] 
These neutral findings might just reflect the fact that the kidneys are well auto-regulated via 
multiple regulatory mechanisms, which are not all dependent on the SNS.[320] 
 
8.4.1 Conclusion 
Renal denervation did not reduce blood pressure in a population of HFpEF, the majority of 
who were normotensive, which is an important safety consideration. The intervention did not 
improve markers of vascular dysfunction, though was underpowered to do so. It remains 
unknown whether pulse wave velocity is a modifiable risk marker in HFpEF. 
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Variables Baseline Change at 3 months Change at 12 Months 
RDT (n=17 Control (n=8) P RDT (n=16) Control (n=8) P RDT (n=17) Control (n=7) P 
Ambulatory Blood Pressure Monitoring (mmHg) 
24hr 
SBP 126.8 ± 15.9 121.1 ± 7.5 0.349 -1.1 ± 13.2 +0.9 ± 11.2 0.727 -2.4 ± 9.7 +1.3 ± 9.4 0.410 
DBP 71.5 ± 9.1 70.0 ± 6.2 0.672 -2.0 ± 7.9 -1.4 ± 6.2 0.847 -2.9 ± 5.8 -1.7 ± 7.4 0.684 
PP 55.2 ± 14.3 51.1 ± 7.6 0.457 +1.1 ± 6.3 +2.0 ± 5.9 0.746 +1.2 ± 6.8 +7.1 ± 13.7 0.166 
Day (0800-2200) 
SBP 128.1 ± 15.9 123.0 ± 7.9 0.400 -1.0 ± 12.7 +1.6 ± 11.4 0.628 -2.7 ± 10.4 +2.1 ± 11.0 0.318 
DBP 72.9 ± 10.4 72.3 ± 5.7 0.863 -2.1 ± 7.6 -1.4 ± 7.0 0.817 -3.7 ± 6.7* -1.9 ± 7.5 0.558 
PP 55.2 ± 14.4 50.8 ± 8.2 0.424 +1.0 ± 6.6 +3.3 ± 5.4 0.413 +0.8 ± 7.1 +3.7 ± 6.4 0.360 
Night (2200-0800) 
SBP 121.2 ± 18.1 113.7 ± 6.7 0.164 +2.0 ± 16.7 -5.9 ± 8.2 0.256 -0.3 ± 12.0 -1.6 ± 9.5 0.800 
DBP 67.9 ± 8.0 63.6 ± 6.8 0.225 -0.7 ± 9.9 -3.0 ± 6.9 0.580 -0.1 ± 6.6 -2.7 ± 9.1 0.438 
PP 53.6 ± 14.5 50.3 ± 7.3 0.480 +2.5 ± 8.0 -2.9 ± 3.6 0.111 -0.5 ± 6.9 +0.7 ± 3.5 0.669 
Table 8.1: Change of average systolic (SBP) and diastolic (DBP) blood pressure in mmHg within the RDT-PEF trial at three months and 
twelve months follow-up .* P<0.05 for within group change. 
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Variables Baseline Change at 3 months Change at 12 Months 
 RDT  Control  P RDT Control  P RDT Control P 
Macrovascular Function 
AA Strain (%) 3.6 (2.2, 7.6) 3.6 (2.6-5.2) 0.977 +0.8 (-1.0, 
1.4) 
+0.1 (-2, 2.7) 0.881 -0.0 (-2.6, 
0.8) 
+1.3 (-2.4, 3.0) 0.260 
AA disten. (10
-
3
.mmHg
-1
) 
0.66 (0.41- 
1.19) 
0.76 (0.42-
0.87) 
0.798 +0.06 (-0.15, 
0.40) 
+0.12 (-0.40, 
0.61) 
0.976 +0.02 (-0.24, 
0.25) 
+0.25 (-0.26, 
0.38) 
0.455 
DA Strain (%) 8.0 (6.8-10.0) 8.2 (4.8-9.6) 0.711 +1.0 (-2.2, 
2.5) 
+1.0 (-0.1, 1.3) 1.000 +0.2 (-1.5, 
1.1) 
-0.3 (-0.7, 1.5) 0.664 
DA disten. (10
-
3
.mmHg
-1
) 
1.44 (1.09-
1.76) 
1.22 (1.06-
1.31) 
0.262 +0.34 (-0.37, 
0.61) 
+0.07 (-0.31, 
0.77) 
0.928 +0.16 (-0.14, 
0.42) 
+0.02 (0.00, 
0.42) 
0.932 
Pulse wave 
velocity (m/s) 
9.61 (5.62- 
11.7) 
9.03 (6.73-
19.66) 
0.466 +0.87 (-0.65, 
2.16) 
+1.26 (-3.61, 
10.86) 
0.815 +1.49 (-0.09, 
3.21) * 
+0.36 (-2.51, 
3.44) 
0.447 
AI (at 75 bpm) 
(%) 
4 (-7, 20) 8 (-3, 17) 0.921 -3 (-10, 11) -4 (-13, 17) 0.831 -2 (-9, 8) +2 (-3, 15) 0.341 
Microvascular Function 
Ln RHI 0.39 ± 0.21 0.56 ± 0.34 0.133 +0.03 ± 0.24 -0.13 ± 0.14 0.098 -0.03 ± 0.21 +0.00 ± 0.42 0.788 
Urine ACR 
(ug/mg) 
40 (10-139) 32 (9-75) 0.665 +3 (-88, 42) -2 (-17, 21) 0.949 +10 (-3, 199) -0 (-26, 12) 0.357 
Table 8.2: Macro and Microvascular Function . AA- ascending aorta; DA- descending aorta; AI- augmentation index; LnRHI- natural log of 
reactive hyperaemic index; ACR- albumin:creatinine; disten.- distensibility 
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Renal Blood 
Flow 
Parameters 
Baseline Change at 12 Months 
RDT  Control  P RDT Control P 
Right Renal Artery 
Flow (L/min) 0.21 ± 
0.06 
0.26 ± 
0.06 
0.181 +0.08 ± 
0.23 
-0.04 ± 
0.07 
0.240 
Pulsatility 
Index 
2.84 
(1.34- 
4.05) 
1.49 (1.33- 
2.22) 
0.180 -0.5 (-
1.85, 
0.42) 
+0.20 (-
0.12, 0.90) 
0.125 
Resistive 
Index 
0.90 ± 
0.12 
0.78 ± 
0.07 
0.038 -0.05 ± 
0.16 
+0.06 ± 
0.14 
0.160 
n 12 6  12 6  
Left Renal Artery 
Flow (L/min) 0.24 ± 
0.09 
0.16 ± 
0.09 
0.121 +0.02 ± 
0.12 
+0.06 ± 
0.13 
0.524 
Pulsatility 
Index 
2.15 
(1.53- 
3.75) 
1.60 (1.57- 
2.09) 
0.221 +0.20 
(-0.97, 
0.64) 
-0.13 (-
0.33, 0.64) 
0.743 
Resistive 
Index 
0.90 ± 
0.10 
0.84 ± 
0.06 
0.198 +0.07 ± 
0.17 
+0.03 ± 
0.15 
0.679 
n 11 5  11 5  
Table 8.3: Renal magnetic resonance derived markers of blood flow 
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 MLWHFQ Peak VO2 BNP E/e’ LAVi LVMi eGFR 
rho P rho P rho P rho P rho P rho P rho P 
24h SBP 0.33 0.11 -0.27 0.19 0.23 0.27 0.23 0.26 0.17 0.41 0.04 0.85 -0.03 0.89 
24h DBP -0.14 0.51 0.35 0.09 -0.04 0.84 -0.17 0.42 0.32 0.12 -0.09 0.68 0.11 0.60 
24h PP 0.50 0.01 -0.52 0.008 0.21 0.31 -.42 0.04 0.15 0.48 0.10 0.65 -0.12 0.58 
AA 
distensibility 
-0.33 0.11 0.05 0.82 0.16 0.44 0.15 0.48 -0.03 0.89 -0.08 0.71 0.31 0.13 
DA 
distensibility 
-0.12 0.57 -0.06 0.77 0.43 0.03 -0.11 0.59 -0.25 0.23 -0.07 0.73 0.03 0.88 
PWV 0.04 0.87 0.01 0.98 -0.23 0.29 -0.09 0.67 0.17 0.44 -0.41 0.05 -0.38 0.07 
AI (75 bpm) 0.22 0.29 -0.26 0.21 -0.10 0.64 0.14 0.52 -0.01 0.97 -0.02 0.93 0.18 0.38 
Ln RHI -0.08 0.77 0.20 0.33 -0.27 0.19 0.42 0.04 0.00 0.99 0.02 0.95 0.16 0.46 
UACR 0.38 0.11 -0.23 0.36 -0.06 0.80 0.12 0.63 0.13 0.61 0.21 0.38 -0.23 0.34 
Mean RBF -0.28 0.27 0.25 0.31 0.06 0.82 -0.27 0.28 -0.10 0.71 -0.55 0.02 0.12 0.65 
Mean PI 0.30 0.23 -0.20 0.42 0.12 0.63 0.03 0.89 -0.26 0.29 0.45 0.06 0.08 0.75 
Mean RI 0.32 0.20 -0.35 0.16 0.36 0.15 0.02 0.95 0.01 0.97 0.23 0.36 -0.04 0.88 
Table 8.4: Spearman’s correlation between baseline vascular function and baseline primary efficacy endpoints and estimated 
glomerular filtration rate (eGFR) . AA- ascending aorta; DA- descending aorta; AI- augmentation index; LnRHI- natural log of reactive 
hyperaemic index; UACR- urine albumin:creatinine; RBF- renal blood flow; PI- pulsatility index; RI- resistive index 
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Figure 8.1: Change in ambulatory systolic blood pressure (SBP) at three months and 12 
months follow-up 
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9 Changes in neuro-humoral profile following renal denervation 
in the RDT-PEF trial 
 
9.1 Introduction 
The evidence for an elevated sympathetic nervous system (SNS) and renin-angiotensin-
aldosterone system as important pathways in HFpEF have been discussed in Chapter 1. In 
this chapter, I will present the effects of RDT on surrogate markers for the SNS and humoral 
biomarkers from the RDT-PEF trial. 
 
9.2 Methods 
These have been discussed in fuller detail in Chapter 3. 
 
Markers of SNS activity were mean 24 hour heart rate (including daytime and nighttime 
averages), random serum and 24 hour urine noradrenaline and heart mediastinum ratio 
(HMR) [early and late] and washout out (WO) rate from cardiac mIBG scintigraphy. The 
humoral markers analysed were random serum renin and aldosterone. These investigations 
were performed at baseline, three months and 12 months follow-up. Cardiac mIBG 
scintigraphy and 24 hour urine catecholamine analysis was performed at baseline and 12 
months. The mIBG images were analysed by an observer blinded to allocation (JB). 
 
Organ specific blood samples for catecholamines were also taken during the renal 
denervation procedure from the 17 patients randomised to receive it. Samples were taken 
prior to renal denervation and immediately after from the two renal veins, coronary sinus and 
aorta. 
 
9.2.1 Statistics 
Data were assessed for normality both subjectively using histograms and statistically using 
the Shapiro-Wilk test. Parametric data are presented as mean ± standard deviation; between 
group comparisons were performed using the independent samples t-test and within group 
comparisons using the paired t-test or repeated measures analysis of variance (ANOVA). 
Non-parametric data are presented as median (quartile 1 and quartile 3); between group 
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comparisons were performed using the Mann-Whitney U test and within group comparisons 
using the Wilcoxon-signed rank or Friedman‟s test. P<0.05 was used as the threshold for 
statistical significance with Bonferroni correction for post-hoc multiple testing. 
 
9.3 Results 
There were no differences between the allocation groups at baseline with respect to the 
parameters of interest (Table 9.1). At baseline, 22 (88%) patients had evidence of abnormal 
sympathetic nerve activity: 18 patients had a late heart:mediastinum (HMR) of <1.6,[321] 19 
had a cardiac wash-out of ≥ 27%[322] on cardiac mIBG imaging and 12 had a plasma 
noradrenaline of >3.50 nmol/L (upper limit of normal for our laboratory). 
 
During the renal denervation procedure, there were differences in noradrenaline assays 
dependent on site of sampling (Table 9.2). Prior to performing ablation and administration of 
any analgesia or sedation, the greatest noradrenaline concentrations were found in the renal 
veins, followed by coronary sinus and finally the aorta (Table 9.2). There were no significant 
changes in noradrenaline levels from any of the four sites after RDT. Adrenaline levels 
appeared to increase after RDT when measured in the aorta alone. 
 
RDT had no a significant effect on neurohumoral profile compared to control (Table 9.1). 
There was no difference in the change of autonomic parameters between patients who 
received anatomically complete RDT compared with those who did not (Table 9.3). 
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 Baseline Change at 3 months Change at 12 Months 
 RDT 
(n=17) 
Control 
(n=8) 
P RDT 
(n=16) 
Control 
(n=8) 
P RDT 
(n=17) 
Control 
(n=7) 
P 
24hr ECG Holter (beats/minute) 
24hr HR 73.2 ± 
13.7 
71.7 ± 
8.9 
0.781 -2.8 ± 
7.4 
+1.1 ± 
5.7 
0.202 -3.4 ± 
7.2 
+1.2 ± 
6.4 
0.162 
Day-time HR 76.5 ± 
15.0 
75.1 ± 
11.5 
0.819 -3.8 ± 
7.8 
+1.8 ± 
5.7 
0.090 -3.9 ± 
8.2 
+2.7 ± 
6.2 
0.068 
Night-time HR 66.5 ± 
11.9 
64.8 ± 
4.8 
0.609 -1.0 ± 
8.3 
-0.3 ± 6.5 0.833 -2.2 ± 
7.2 
-1.8 ± 8.6 0.907 
mIBG 
HMR early 1.61 
(1.50,  
1.80) 
1.56 
(1.46, 
1.72) 
0.669 
 
+0.01 
(-0.13, 
0.10) 
+ 0.00 (-
0.01, 
0.33) 
0.166 
HMR late 1.49 ± 
0.18 
1.52 ± 
0.19 
0.730 -0.00  
± 0.11 
+0.10  ± 
0.11 
0.059 
WO (%) 36.7 ± 
15.2 
33.0 ± 
16.6 
0.591 -3.8  ± 
19.1 
+0.8 ± 
8.8 
0.552 
Plasma Neurohormones 
Noradrenaline 
(nmol/l) 
3.91 ± 
1.29   
3.34  ± 
0.85 
0.270 -0.05 ± 
2.37 
+0.91  ± 
1.62 
0.313 -0.04 ± 
1.78 
-0.03 ± 
0.91 
0.991 
Adrenaline 
(nmol/l) 
0.45 ± 
0.19 
0.52 ± 
0.10 
0.360 -0.12 ± 
0.29 
-0.06 ± 
0.13 
0.571 +0.05 
± 0.21 
-0.02 ± 
0.16 
0.457 
Aldosterone 
(pmol/L) 
370 
(195, 
525) 
405 (158, 
743) 
0.711 +65 (-
98, 
375) 
+5 (-265, 
273) 
0.610 -20 (-
245, 
70) 
-30 (-
330, 150) 
0.710 
Renin 
(nmol/L/hr) 
1.9 (0.4, 
9.0) 
1.8 (0.5, 
8.4) 
0.887 -0.2 (-
3.3, 
0.7) 
+0.9 (0.0, 
5.1) 
0.070 +0.2 (-
0.4, 
3.0) 
-0.5 (-
3.1, 0.1) 
0.160 
ARR (pmol/L 
per nmol/L/hr 
220 (27, 
900) 
280 (32, 
605) 
0.875 +57 (-
145, 
312) 
-24 (-
283, 12) 
0.115 -50 (-
195, 
48) 
+72 (-73, 
242) 
0.205 
24 hour Urine Catecholamines 
Noradrenaline 
(nmol/24hrs) 
248 ± 98 245 ± 68 0.920  -28 ± 
36 
-20 ± 85 0.762 
Adrenaline 
(nmol/24hrs) 
28 
(14.5- 
34.0) 
27 (16.8- 
36.5) 
0.932 +3 (-
6.5, 
31.5) 
-2 (-9.0, -
1.0) 
0.234 
Dopamine 
(nmol/24hrs) 
1066 ± 
425 
1120 ± 
294 
0.752 -169 ± 
429 
+129 ± 
354 
0.120 
Table 9.1 Baseline and changes at 3 and 12 months of neurohumoral markers in the 
RDT-PEF population. Paired t-test or Wilcoxon-signed rank test for paired data: *P<0.05  
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 Right Renal 
Vein (n=15) 
Left Renal 
Vein (n=15) 
Coronary 
Sinus 
(n=16) 
Aorta 
(n=16) 
P 
(sampling 
site) 
Noradrenaline 
Before RDT 2.90 ± 1.05* 3.05 ± 1.27* 2.35 ± 0.95 1.78 ± 0.67 <0.001 
After RDT 2.40 ± 1.15 2.51 ± 1.19* 2.04 ± 1.01 1.98 ± 0.86 0.009 
P (before vs 
after) 
0.113 0.244 0.128 0.254  
Adrenaline 
Before RDT 0.43 (0.32, 
0.55) 
0.46 (0.30, 
0.91) 
0.55 (0.43, 
0.66) 
0.42 (0.29, 
0.57) 
0.593 
After RDT 0.39 (0.29, 
0.57) 
0.64 (0.54, 
1.09) 
0.48 (0.39, 
0.62) 
0.59 (0.32, 
0.67) 
0.230 
P (before vs 
after) 
0.629 0.083 0.752 0.026  
Table 9.2: Intra-procedural catecholamine measurements immediately before and after 
renal denervation. *P<0.05 in pairwise comparison compared to aorta samples 
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Endpoints Change at 3 months  Change at 12 months  
Complete 
Ablation 
(n=4) 
Incomplete 
Ablation 
(n=12) 
P Complete 
Ablation 
(n=5) 
Incomplete 
Ablation 
(n=12) 
P 
24hr ECG Holter 
24hr HR -5.4 ± 11.4 -2.0 ± 6.0 0.440 -5.1 ± 8.3 -2.6 ± 7.0 0.540 
Day-time HR -6.3 ± 12.1 -2.9 ± 6.3 0.478 -6.0 ± 7.5 -3.0 ± 8.6 0.505 
Night-time HR -3.7 ± 10.6 -0.1 ± 7.7 0.466 -3.2 ± 10.6 -1.8 ± 5.9 0.742 
mIBG 
Early HMR  -0.04 (-
0.14, 0.03) 
+0.05 (-
0.12, 0.25) 
0.383 
Late HMR -0.07 ± 
0.12 
+0.03 ± 
0.10 
0.099 
Washout rate 
(%) 
+0.69 ± 
21.05 
-5.67 ± 
18.91 
0.549 
Plasma Neurohormones 
Noradrenaline 
(nmol/l) 
-0.62 ± 
3.41 
+0.19 ± 
1.93 
0.541 +0.27 ± 
1.95 
-0.16 ± 1.78 0.664 
Adrenaline 
(nmol/l) 
-0.14 (-
0.44, 0.11) 
-0.10 (-
0.31, 0.09) 
0.790 +0.04 (-
0.12, 0.16) 
+0.01 (-
0.10, 0.24) 
0.978 
Aldosterone 
(pmol/L) 
+50 (-285, 
265) 
+65 (-95, 
395) 
0.521 -120 (-415, 
35) 
+40 (-88, 
118) 
0.254 
Renin 
(nmol/L/hr) 
+3.6 (-3.0, 
8.4) 
-0.6 (-3.8, 
0.0) 
0.203 +0.6 (-17.8, 
4.9) 
+0.3 (-0.4, 
3.6) 
0.976 
ARR (pmol/L 
per nmol/L/hr 
-145 (-196, 
-32) 
+141 (20, 
608) 
0.050 -142 (-261, 
7) 
-13 (-511, 
174) 
0.518 
24 hour Urine Catecholamines 
Noradrenaline 
(nmol/24hrs) 
 -4.8 ± 22.7 -26.9 ± 
100.5 
0.484 
Adrenaline 
(nmol/24hrs) 
+15 (-5, 
38) 
+3 (-8, 28) 0.459 
Dopamine 
(nmol/24hrs) 
+10 ± 312 -244 ± 460 0.281 
Table 9.3: Subgroup analyses comparing change in autonomic assessments between 
those patients that received anatomically completed ablation and those with incomplete. 
NA- noradrenaline; HMR- heart: mediastinum form mIBG imaging; ARR- aldosterone:renin. 
Data are presented as mean ± standard deviation or median (quartile 1, quartile 3). P 
represents Mann-Whitney U test. 
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9.4 Discussion 
My initial hypothesis relied on RDT being successfully able to attenuate the sympathetic 
nervous system. Using several complementary modalities, I have demonstrated no effect of 
RDT on the SNS. Several factors may underlie this finding: 1) the small sample size may be 
underpowered to detect a difference; 2) RDT using the Symplicity™ catheter may not alter 
sympathetic tone; and 3) our techniques used to quantify the SNS may have been 
inappropriate. 
 
Sample size was estimated with a type 1 error rate of 0.05 and 80% power, using the formula: 
16sd
2
/d
2
 (where sd is the standard deviation of the between group difference in change and d 
is the expected treatment effect).[323] The treatment effect was modelled as 5 beats per 
minute drop in heart rate or a 15% change from mean baseline values. Table 9.4 highlights 
that our study was underpowered for all the parameters. 
 
 SD Expected delta Sample Size 
HR 6.9 5 61 
HMR Late 0.12 0.15 28 
WO 16.7 5.5 295 
Noradrenaline 1.6 0.6 228 
Urine 
Noradrenaline 
73 37 71 
Aldosterone 345 86 515 
Renin 18.6 1.1 9149 
Table 9.4: Sample size estimates for select neuro-humoral parameters using between 
group standard deviation of change (SD) derived from the RDT-PEF study 
 
Animal studies using trans-catheter RDT (as opposed to surgical denervation) have 
convincingly shown that the technology can reduce neurohumoral activation. Indeed in 
healthy and cardiovascular disease (hypertension, heart failure, atrial fibrillation, obstructive 
sleep apnoea) models, RDT has reduced renal nerve activity (renal tissue noradrenaline 
concentration[164, 324-328], histological renal nerve count [164, 325-331]), cardiac 
sympathetic activity (trans-cardiac noradrenaline[324], histological cardiac sympathetic nerve 
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count[324]), non-specific sympathetic activity (plasma noradrenaline)[332] and humoral 
activity (angiotensin II, aldosterone, renin).[332-335]  
 
These findings have not been reproduced in man. The main reason for this is that in clinical 
studies it is not possible to perform renal artery histological analysis of renal tissue 
quantification for noradrenaline, which are optimal markers of the RDT on renal sympathetic 
anatomy and function.[336] Instead renal noradrenaline spillover, muscle sympathetic nerve 
activity and serum hormones have been used as markers of the SNS. The studies which have 
reported on the change of these parameters are small (n<50), uncontrolled and exposed to 
bias. Their results are largely equivocal, with some showing change and others failing to do 
so.[156, 175-178, 182, 203, 208, 217, 337-342] The randomised clinical trials in resistant 
hypertension have failed to show an effect on heart rate following RDT.[195, 199, 200, 343, 
344] The RDT-PEF study uniquely adds to the literature mIBG data and reports on a 
previously unstudied HFpEF population but consistent with the previous reports failed to 
show an effect of RDT on the SNS beyond that seen in the control arm. In further analysis, 
we found no association between the extent of renal artery ablation and changes in SNS 
markers.  
 
A possible explanation for this negative finding is that the Symplicity™ catheter is unable to 
penetrate the renal artery adventitia to destroy a critical mass of sympathetic nerves. The only 
human histology data available following RDT (using the Symplicity™ catheter)  was from a 
post mortem examination of a woman who died 12 days after the procedure from an 
ascending aorta dissection deemed unrelated to the procedure.[274] Histological examination 
of the renal arteries showed that the maximum depth of thermal injury was only 2mm, which 
from recent human cadaver studies is insufficient for the majority of renal nerves.[158] From 
a study in pigs, the investigators suggested that at least 50% of the renal nerves need to be 
ablated to achieve a significant drop in renal noradrenaline concentration.[345] This might be 
more easily achievable if more powerful RDT catheters, which can create deeper lesions and 
a strategy of performing post bifurcation or distal artery (where nerves course closer to the 
renal artery lumen) denervation, are adopted.[158, 346]  
 
A common criticism of the RDT in resistant hypertension literature is that patients are not 
chosen based on their degree of impairment in the sympathetic tone. This is true for the RDT-
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PEF trial as well, but 22/25 (88%) of patients had some evidence of an abnormal SNS. 
Furthermore, in organ specific analysis, noradrenaline outflow from the kidneys was shown 
to be greater than that from the heart, adding to literature citing the importance of the renal 
nerves in heart failure.  
 
The organ specific analysis performed immediately after denervation reflects not only the 
effects of renal sympathetic nerve disruption but also pain, analgesia, sedation and associated 
hypotension, which limits interpretation.[347, 348] Surprisingly, the whole process of RDT 
increased adrenaline levels when measured in the aorta in our patients. This may be a false 
positive result, particularly as similar changes were not found in coronary sinus or renal vein 
samples. However, even if this finding was true, in the acute setting it is not a clinically 
relevant change and hence was unlikely to be detrimental to our patients who were 
haemodynamically stable from the outset. Further dedicated studies examining the acute 
effect of the RDT procedure on the SNS would be beneficial especially as some centres have 
enthusiastically been performing RDT in haemodynamically unstable patients, such as those 
in ventricular tachycardia storm.[349] 
 
Another limitation of this analysis is that a complete autonomic assessment was not 
performed in all the patients. Notably, neither microneurography nor organ-specific 
noradrenaline spillover were undertaken. These would have provided further valuable 
mechanistic information, however, they require not only specialised equipment and 
experience to perform accurately but also would have added an additional burden of invasive 
assessments on our patients.  
 
9.4.1 Conclusion 
There was evidence of heightened SNS responses in the majority of the patients recruited into 
the RDT-PEF trial. RDT when compared to on-going medical management alone did not 
alter any of the markers for neurohumoral activation.  
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10 Conclusions 
 
This thesis sought to evaluate the role of RDT in patients with HFpEF. The first and probably 
most relevant finding of this thesis is the discrepancy between the reported prevalence of 
HFpEF in the literature and the experience I had whilst screening for the RDT-PEF trial. 
Population studies have suggested that HFpEF is very prevalent, when defined just by an 
ejection fraction threshold, it accounts for 30-60% of all heart failure. However, once more 
stringent selection criteria are applied, such as exclusion of severe valve disease and old age 
(>85 years), only 1% of the heart failure population remain eligible for an HFpEF trial.[264] I 
found studying such an unexpectedly rare population to be difficult. 
 
The RDT-PEF trial recruited 25 patients and was underpowered for the primary efficacy 
endpoint. However, as the first randomised controlled trial to be completed in patients with 
HFpEF, it did provide reassuring safety data with up to 12 months of follow-up. It also serves 
as a reminder that „safe‟ a commonly cited adjective with reference to RDT is not equivalent 
to risk free. Two patients in the RDT-PEF trial required balloon angioplasty for acute renal 
artery stenosis developing during the procedure. In both cases there were no lasting adverse 
consequences but this indicates that the oedema/severe spasm in this older population can be 
more severe than the rapidly reversible changes described in previous trials of resistant 
hypertension. A secondary efficacy analysis suggested that patients who received RDT had 
an improvement in a composite clinical endpoint score, which subsequently disappeared at 12 
months. Biases due to non-blinding may be an important contributor to this finding and the 
importance of a blinded-sham control in interventional trials that use surrogate endpoints 
cannot be stressed enough.[196] Alternatively, a biological explanation might be 
reconnection of ablated renal nerves as has been noted in animal models.[164] 
 
The vascular and autonomic sub-studies failed to show that RDT improves any of the 
markers tested. Importantly, it showed that RDT did not harmfully lower blood pressure in 
patients who are normotensive, which was a major concern when trials evaluating RDT in 
heart failure were originally conceived.  
 
Looking to the immediate future, two other research groups are undertaking a similar project 
to the RDT-PEF trial: DIASTOLE (Netherlands) and RESPECT-HF (New Zealand, 
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Singapore). Our group has met with the respective leads of each of these trials and have 
proposed a merger of clinical datasets once they are ready. This will hopefully increase the 
power of any findings; however, primary data collection will not be complete by these groups 
till after April 2016. 
 
With respect to HFpEF, it is becoming accepted that a strategy of matching specific 
treatments to phenotypes of HFpEF will need to be adopted by clinical studies.[151] This 
approach will impose additional eligibility criteria, which will make recruitment more 
difficult. To overcome this challenge, it is important that all heart failure units are involved in 
the evaluation and diagnosis of all patients with suspected heart failure and furthermore all 
units should collaborate in research networks such that suitable patients with HFpEF can be 
easily put forward for clinical trials. This infrastructure currently does not exist in UK. 
 
Finally, renal denervation as I originally knew it at the start of this body of work in 2012 is 
almost extinct.[156] In the past three years our understanding of the procedure has rapidly 
expanded. In particular histological data suggest that renal nerves are more likely to be 
accessible to radiofrequency energy in the distal renal artery even after bifurcation, which 
was not the original recommended approach.[158, 325] Secondly, it is better appreciated that 
the Symplicity™ single electrode catheter has significant limitations: 1. It is difficult to 
achieve a circumferential anatomical ablation with it; 2. It cannot be used in arteries smaller 
than 3mm; and 3. It is unclear whether it is powerful enough to create thermal lesions deep 
enough to reach the renal sympathetic nerves.[275] It is unknown whether the newer and 
possibly more powerful multi-electrode catheters, some of which can create lesions up to 
10mm deep and enter vessels as small as 3mm, will be able to attenuate the SNS better and 
safely.[275]  
 
The planning and conduct of future trials of renal denervation in heart failure will hopefully 
benefit from our initial experiences with the RDT-PEF trial. 
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